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Abstract 
Asthma and bacterial pneumonias are major causes of human mortality and 
morbidity throughout the world. To date many studies have investigated the 
possibility that bacteria exacerbate asthma but only a handful consider that asthma 
may cause bacterial infections. Recent clinical evidence suggests that bacterial 
infections cause serious complications in patients with asthma and that asthmatics 
show a 2-fold increased risk of invasive pneumococcal disease. This thesis 
examines the molecular mechanisms causing susceptibility of house dust mite 
(HDM) exposed lungs to bacterial infection.  
The main finding of this thesis is that HDM-induced allergic airways disease 
increases susceptibility to Streptococcus pneumoniae infection. Furthermore, the 
molecular pathways leading to the production of neutrophil chemoattractants in the 
lung are compromised and that despite the complexity of anti-bacterial pathways that 
are disrupted, the re-introduction of a single chemokine to the lungs with allergic 
airway disease enables clearance of S. pneumoniae that would otherwise prove 
fatal. However, a reduction in HDM-induced eosinophilia seen in ST2 deficient mice 
does not restore anti-bacterial immunity. 
This deficit in anti-bacterial immunity in HDM exposed lungs is associated with a 
change in resident alveolar macrophages into an alternatively activated phenotype, 
characterised by high mRNA and protein levels of RELMα, Ym1 and Arg1. These 
altered alveolar macrophages produce considerably less TNFα in response to Toll-
Like Receptor (TLR) stimulation that is not a result of reduced TLR mRNA levels but 
due to an upregulation of TLR negative regulators particularly A20. A20 targets 
TRAF-6 that is found upstream of NF-κB activation. To prove a causal link naïve 
alveolar macrophages were transferred into allergic lungs prior to bacterial infection; 
such lungs handled the infection better confirming that alveolar macrophages are 
important in initiating the anti-bacterial response. Overall our findings highlight a 
change in specific innate immune pathways in the allergic lung that participate in 
susceptibility to bacterial pneumonia.  
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CHAPTER 1 
1.1 Asthma 
1.1.1 Burden of asthma and pneumonia 
Respiratory diseases are responsible for a significant proportion of morbidity and 
mortality globally. Asthma is a major respiratory public health problem affecting 300 
million people worldwide1,2. Although the incidence of asthma is variable between 
populations, the prevalence has risen over the past few decades3. In the UK, 3.4 
million people have asthma2. Asthma has a high economic burden costing the UK’s 
National Health Service £750 million per year4 and is an important cause of 
incapacity in terms of absence from school and work5. The World Health 
Organisation (WHO) ranks lower respiratory diseases as the 3rd leading cause of 
death worldwide6 (Table 1.1) and Streptococcus pneumoniae (S. pneumoniae), also 
known as the pneumococcus is a major cause of respiratory bacterial infections 
worldwide. In 2000, there were 14.5 million global pneumococcal cases7. The main 
forms of severe S. pneumonia disease are pneumonia, meningitis and sepsis8. The 
WHO estimates 1.6 million annual deaths due to pneumococcal diseases9. 
Therefore, asthma and bacterial infection independently affect millions of people 
worldwide causing significant mortality and an associated high economic burden.  
 
 World Death in millions % Death 
1 Ischaemic heart disease 7.25 12.8 
2 Stroke and other cerebrovascular 
disease 
6.15 10.8 
3 Lower respiratory infections 3.46 6.1 
4 Chronic obstructive pulmonary 
disease 
3.28 5.8 
5 Diarrhoeal diseases 2.46 4.3 
Table 1.1: Top 5 causes of death in the world as on the World Health Organisation website 
accessed on 31 Jan 2012 (factsheet No. 310 updated June 2011)6. 
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1.1.2 Risk of infection in asthma aetiology  
Lower respiratory tract infections are associated with the initiation of asthma, but 
more commonly cause asthma exacerbations. There is increasing evidence to 
indicate that early childhood infections may affect the subsequent sensitisation to 
allergens and development of asthma. For example, there is an inverse relationship 
between measles in childhood and allergen sensitisation10. Similarly, children who 
exhibited strong positive tuberculin skin tests, indicating natural exposure to 
tuberculosis, have reduced serum immunoglobulin (Ig)-E, T helper type (Th)-2 
cytokines and fewer symptoms of asthma10. However, not all infections are 
protective, wheezing respiratory syncytial virus (RSV) infected infants are more likely 
to develop asthma by their third birthday11. These results suggest that early 
childhood infections modulate immune responses that can initiate or inhibit allergic 
inflammatory responses later in life.  
There is a large body of evidence that viral infections are a potent trigger of asthma 
symptoms. It is reported that 80% of childhood asthma exacerbations and 50% of all 
adult asthma attacks are associated with viral infections12. Most commonly identified 
viruses linked to wheezing under the age of 2 years are RSV (50-60%) and 
rhinovirus (RV; 30%), while RV account for 60% of viruses in children over 2 years of 
age13. These viruses were mainly detected by PCR assays. Viruses cause increased 
airway inflammation affecting airway function. However, the association between 
respiratory viral infections and asthma exacerbations is not completely understood.  
The most common cause of viral exacerbations of asthma is RV. In one study, a 
respiratory virus was associated in 78% of acute exacerbations of asthma and of 
these, 83% were RV14. RV predominately infect the conducting airways by 
interacting with intercellular adhesion molecule 1 (ICAM-1) or low-density 
lipoproteins receptors on epithelium that internalise the virus. The virus initiates a 
cascade of molecular pathways resulting in activation of NF-κB and the release of a 
variety of cytokines and chemokines i.e. interleukin (IL)-17F, granulocyte 
macrophage colony-stimulating factor (GM-CSF) and IL-815. The asthmatic epithelial 
cells also facilitate virus penetration into the airways and then into the circulation- 
this is linked to abnormal bronchial epithelial cell responses to RV infection as a 
result of a major defect in interferon (IFN)-β secretion and delayed apoptosis of 
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bronchial epithelial cells15. In addition, in vitro, studies show that Th2-associated 
cytokines in the asthmatic lung increase ICAM-1 that is the major RV receptor. This 
would facilitate viral attachment to epithelial cells and entry.  
Of the pathogens studied, viruses have received the most attention. However, 
retrospective studies in humans establish a strong relationship between asthma and 
S. pneumonia infections. In 2005, Talbot et al showed asthmatics to have a 2-fold 
increased risk of invasive pneumococcal disease (IPD)16 and a number of other 
studies published since adds support to this finding. A retrospective study on 1282 
patients with IPD in Finland show a 5% disease burden attributed to asthma17. In a 
recent study, children born to asthmatic mothers were investigated for neonatal 
airway colonisation and pneumonia until three years of age. 21% of the children 
were colonised with S. pneumonia, Haemophilus influenza and/or Moraxella 
catarrhalis at four weeks of age and colonisation with at least one of these bacteria 
was significantly associated with increased incidence of pneumonia18.  
Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus 
complications are often reported in lung inflammatory diseases including asthma, 
chronic obstructive pulmonary disease (COPD) and influenza (Table 1.2). The 
similarity in the bacterial complications that occur following these conditions could be 
driven by a mechanism common to all for example the casautive agents of these 
disorders alter respiratory epithelial barrier. Although, the type of infiltrating cells are 
different in asthma and COPD; eosinophils, mast cells and Th2 cells dominate in 
asthma, whereas neutrophils and Th1 cells are prominent in COPD. However, there 
are subphenotypes of these diseases that are similar, for example some COPD 
patients present with high sputum eosinophil counts similar to asthma, while some 
asthmatics have high neutrophil numbers. Eosinophilic airway inflammation plays a 
role in exacerbations of both asthma and COPD and treatments to lower eosinophilia 
significantly reduce the frequency of exacerbations19. In a study of 82 patients with 
moderate-severe COPD who received therapy to minimise eosinophilic inflammation 
(>3% of non-squamous sputum cells) experienced fewer severe exacerbations 
(defined by score of symptoms, quality of life and lung function)19. Furthermore, a 
study in asthmatics with high sputum eosinophil counts after discontinuation of 
inhaled corticosteroids augmented asthma exacerbations20. Sputum eosinophilia is 
associated with corticosteroid responsiveness21, whereas an exacerbation 
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characterised by high bacterial load will have a favourable response to antibiotics. In 
a randomised control trial, treatment targeted to sputum eosinophil counts 
significantly reduced asthma exacerbations in patients with severe asthma with 
eosinophilic phenotype22. Neutrophilic inflammation also predominates in some 
patients with severe asthma 23,24. Asthmatics with viral infection have an increase in 
sputum neutrophils and neutrophil elastase25. COPD exacerbations are associated 
with impaired lung function and increased sputum neutrophilia as a result of viral 
(48.4%) and bacterial (54.7%) infections26. Furthermore, airway neutrophilia 
correlated with exacerbation severity regardless of the cause of infection26 .  
Inhaled corticosteroids have broad anti-inflammatory effects and are widely used in 
the treatment of asthma and COPD. Inhaled corticosteroids do not alter disease 
progression but reduce AHR, exacerbations and mortality in all age groups27. A 
study in Lothian, UK involving 490 COPD patients admitted with community-acquired 
pneumonia of which 76.7% were inhaled corticosteroid users show no difference on 
outcome and in pneumonia severity28. Whereas, another study showed the 
probability of having pneumonia was higher among subjects receiving medications 
containing inhaled corticosteroids compared with the placebo group29. However, in 
this latter study, the lack of effect of inhaled corticosteroids on mortality and disease 
progression may reflect resistance to the anti-inflammatory effects of corticosterioids 
in COPD patients. Another retrospective study also show an improved survival of 
COPD patients with inhaled corticosteroids from all causes30. 
Table 1.2: Bacterial species involved in exacerbations of lung inflammatory disorders.  
 Influenza RSV COPD Asthma 
Human studies 
Typical Bacteria  
Streptococcus 
pneumoniae 
 31,32   33   34,35  16,36-38  
Haemophilus 
influenzae 
 39   40  34,35  36,37,41 
Moraxella 
catarrhalis 
 42  43  35  36,37 
Staphylococcus 
aureus 
 39,44  45  45  46 
Atypical bacteria 
 
 
Chlamydia 
pneumoniae 
   47  48,49 
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Mycoplasma 
pneumoniae 
  50    48,49 
Animal studies 
Typical Bacteria  
Streptococcus 
pneumoniae 
 51-53  54   55  56 
Haemophilus 
influenzae 
 57   58  59 
Moraxella 
catarrhalis 
  60   
Staphylococcus 
aureus 
 61,62    63,64 
Atypical bacteria 
 
 
Chlamydia 
pneumoniae 
    65 
Mycoplasma 
pneumoniae 
    66,67 
All references restricted to examples. RSV-Respiratory syncytial virus; COPD-Chronic 
obstructive disease. 
Blank boxes: To our knowledge no reported complication of the bacteria in the associated 
lung condition and this table was originally made for a review in future microbiology 
submitted in 2012 68.  
 
There is growing evidence for the role of atypical bacteria such as Mycoplasma 
pneumoniae (M. pneumoniae) and Chlamydia pneumoniae (C. pneumoniae) in 
asthma exacerbations. For example, one study found 56% of asthmatics positive for 
C. pneumoniae, M. pneumoniae or both compared to 9% of controls69. One group 
associate the increased M. pneumoniae susceptibility to downregulated toll-like 
receptor (TLR)-2 and IL-6 production during M. pneumoniae infection in ovalbumin 
(OVA)-induced allergic inflammation70. Low-level M. pneumoniae infection enhances 
Th2 responses (IL-4 and exotaxin), whereas a high-level exposure reduced lung 
eosinophilia in OVA-induced allergic airway disease71. Chlamydia muridarum 
infection can subvert dendritic cells from a protective Th1 response to a non-
protective Th2 response, which promote asthma72. Furthermore, IL-13 increases 
susceptibility to Chlamydia muridarum infection as the cytokine reduces uptake of 
bacteria by macrophages73. The role of bacteria in asthma exacerbation is 
strengthened by studies using anti-atypical bacteria antibiotics (macrolides and 
ketolides) where improvement in asthma symptoms is noted74. However, some 
antibiotics possess anti-inflammatory properties making the role of atypical bacteria 
controversial in asthma exacerbations. It should be noted that in most studies to date 
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the role of outgrowth of specific bacterial commensals have been ignored. This is 
mostly due to their detection by culture in the laboratory. More recently, Hilty et al 
have shown the bronchial tree to contain a characteristic microbiota by molecular 
analysis of the polymorphic bacterial 16S ribosomal RNA gene, and suggest that this 
microbiota is altered; Haemophilus, Moraxella and Neisseria species being more 
frequent in bronchi of asthmatics41. This study also shows that the airways are not 
sterile. 
 
1.1.3 Genetic susceptibility to asthma 
Data suggests 40-60% of the risk of developing asthma can be linked to genetic 
factors75. A number of alleles, chromosomes and polymorphisms are associated with 
asthma susceptibility (Table 1.3).  
Gene Chromosome Function and pathway 
GSTM1 1p13.3 Environmental and oxidative stress- 
detoxification  
FLG 1q21.3 Epithelial barrier integrity 
IL10 1q31-q32 Immunoregulation 
CTLA4 2q33 T cell response inhibition and 
immunoregulation 
IL13 5q31 Th2 effector functions 
IL4 5q31.1 Th2 differentiation and IgE induction 
CD14 5q31.1 Innate immunity-microbial recognition 
SPINK5 5q32 Epithelial serine protease inhibitor 
ADRB2 5q31-q32 Bronchial smooth muscle relaxation 
HAVCR1 5q33.2 T cell response regulation-HAV receptor 
LTC4S 5q35 Cysteinyl leukotriene biosynthesis-
inflammation 
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LTA 6p21.3 Inflammation 
TNF 6p21.3 Inflammation 
HLA-DRB1 6p21 Antigen presentation 
HLA-DQB1 6p21 Antigen presentation 
HLA-DPB1 6p21 Antigen presentation 
GPRA 7p14.3 Regulation of cell growth and neural 
mechanisms 
NAT2 8p22 Detoxification of drugs and carcinogens 
FCERIB 11q13 High affinity Fc receptor for IgE 
CC16 11q12.3-q13.1 Epithelium derived anti-inflammatory 
protein 
GSTP1 11q13 Environmental and oxidative stress- 
detoxification  
IL18 11q22.2-q22.3 Induction of IFNγ and TNF 
STAT6 12q13 IL-4 and IL-13 signalling 
NOS1 12q24.2-q24.31 Nitric oxide synthesis- cell-cell 
communication 
CMA1 14q11.2 Mast-cell chymotryptic serine protease 
IL4R 16p12.1-p12.2 α-chain of the IL-4 and IL-13 receptors 
CCL11 17q21.1-p21.2 Epithelium derived eosinophil 
chemoattractant 
CCL5 17q11.2-q12 Monocyte, T cell and eosinophil 
chemoattractant 
ACE 17q23.3 Inactivation of inflammatory mediators 
TBXA2R 19p13.3 Smooth-muscle contraction, 
inflammation 
TGFB1 19q13.1 Immunoregulation, cell proliferation 
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ADAM33 20p13 Cell-cell and cell-matrix interactions 
GSTT1 22q11.23 Environmental and oxidative stress-
detoxification 
ORMDL3 17q21 Negative regulator of sphingolipid 
synthesis 
IL33 9 Inducing Th2 associated cytokines 
TSLP 13q31.1 Eosinophilic esophagitis 
IL1RL1 2 IL-33 receptor (ST2) 
SMAD3 15 Transcriptional modulator 
 
Table 1.3: A list of susceptibility genes for asthma. Adapted from 76-78   
ACE, angiotensin I converting enzyme 1 (also known as peptidyl-dipeptidase A); ADAM33, a 
disintegrin and metalloproteinase domain 33; ADRB2, β2 adrenergic receptor; CC16, Clara 
cell-specific 16 kD protein (also known as SCGB1A1); CCL11, CC-chemokine ligand 11 
(also known as eotaxin1); CCL5, CC-chemokine ligand 5 (also known as RANTES); CD14, 
monocyte differentiation antigen 14; CMA1, chymase 1, mast cell; CTLA4, cytotoxic T 
lymphocyte antigen 4; FCERIB, high-affinity Fc receptor for IgE β-chain; FLG, filaggrin; 
GPRA, G-protein-coupled receptor for asthma susceptibility (also known as NPSR1, and 
GPRA154); GSTM1, glutathione S transferase M1; GSTP1, glutathione S transferase P1; 
GSTT1: glutathione S transferase T1; HAVCR1, hepatitis A virus cellular receptor 1 (also 
known as TIM1); IL, interleukin; IL4R, interleukin-4 receptor (α-chain); LTA, lymphotoxinα 
(also known as TNFβ); LTC4S, leukotriene C4 synthase; NAT2, N acetyltransferase 2; 
NOS1, nitric oxide synthase 1 (neuronal); SPINK5, serine protease inhibitor, Kazal-type, 5; 
STAT6, signal transducer and activator of transcription 6; TBXA2R, thromboxane A2 
receptor; TGFB1, transforming growth factor-β1; TNF, tumour necrosis factor; SMAD 3, 
mothers against decapentaplegic homologue); IL1RL1 (ST2) and IL1 receptor accessory 
protein activate IL-33; TSLP, thymic stromal lymphopoietin.  
 
1.1.4 Allergic sensitisation 
Asthma is a multifactorial disease but there is growing evidence for the role of local 
immune events in development of allergic airway inflammation. Asthma is 
characterised by reversible airway obstruction, mucus hyper-secretion, airway 
	   	   Chapter	  1:	  Introduction	   	  
29	  
	  
remodelling and infiltration of eosinophils and Th2 cells79. Asthma sub-phenotypes 
(allergic, non-allergic, occupational) have differing pathology, clinical expression and 
response to treatment80,81. Asthma occurs not purely a result of allergen exposure; 
nonetheless allergic asthma is the most common form82. Common allergens include 
HDM, pollen, cat dander and fungi. It is reported that 60-100% of asthmatics are 
sensitised to HDM83. In Europe, the most predominating species of HDM is 
Dermatophagoides pteronyssinus (Der p)84. Allergens of Der p have different 
biochemical properties but most are digestive enzymes that are secreted in their 
faeces. For example, Der p 1 has cysteine and serine protease activities85.  
 
1.1.5 House dust mite and its pathogenesis 
10-15% of individuals in the western world have asthma with 15% of asthmatics 
having daily symptoms and a large proportion of asthmatics, 85% are HDM 
allergic82,86. HDM’s environment contains bacteria, lipopolysaccharide (LPS), β-
glucans and fungi87. HDM extract consists of whole mites, faecal pellets, nymphs, 
eggs and culture media88. HDM has a lifetime of 10 weeks and produces 2000 fecal 
particles82. The major HDM species are Der p and Dermatophagoides farinae (Der f), 
however, in the UK Der p predominates84. Der p has 21 allergens (Table 1.4) and 
absolute IgE binding measurement shows 50% binding associated with Der p 1 and 
2 and 30% was equally contributed by Der p 4, 5 and 784.  The level of Der p 1 in 
house dust is 100-10,000 ng/g of dust88. 
Nomenclature Biochemical property Dermatophagoides Allergenicity 
Group 1 Cysteine protease Dominant 
Group 2 ML domain lipid-binding protein Dominant 
Group 4 Α-amylase Midpotency 
Group 5 Unknown Midpotency 
Group 7 Lipid-binding protein Midpotency 
Group 21 Unknown Midpotency 
Table 1.4: Important HDM allergens and their biochemical properties. More than 20 HDM 
allergens groups have been defined based on sequence and functional homologies. 
Adapted from84. ML=MD-2 related lipid-recognition. 
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The host immune response to HDM comprises both innate and antigen-specific 
adaptive immunity. HDM in the airway first comes in contact with airway epithelial 
cells. HDM can act through a number of cell surface receptors on airway epithelial 
cells and HDM-induced TLR4 signalling through epithelial cells leads to secretion of 
TSLP, GM-CSF, IL-25 and IL-33 cytokines associated with induction of allergic 
inflammation89. These cytokines can induce allergic airway disease without the help 
of Th2-derived cytokines. Over-expression of TSLP and intranasal administration of 
IL-25 result in AHR90. IL-33 is member of the IL-1 family and signals through T1/ST2 
receptor (ST2L, IL-33 receptor) on Th2 cells, nuocytes and macrophages91. 
Exogenous administration of IL-33 causes eosinophilia, induction of Th2 cytokines 
and mucus hypersecretion, whereas blocking the receptor abolishes many features 
associated with Th2 responses92,93. ST2 is present in two forms, ST2L and soluble 
ST2. The extracellular domain is common to ST2 and ST2L; however, sST2 lacks 
the transmembrane and intracellular Toll-interleukin 1 receptor domains. ST2L is 
expressed on many cell types including macrophages 94, eosinophils 95, vascular 
endothelial96 and mast cells97 but is preferentially expressed in murine and human 
Th2 cells 98. A newly described subset of cells, innate lymphoid cells also express 
ST2L even though they are lineage negative. These lineage negative innate 
lymphoid cells produce IL-5 and IL-13 in response to in vivo HDM exposure99 and 
are thought to be involved in allergic responses in vivo. Although anti-ST2 antibody 
treatment attenuates Th2 responses100, ST2 deficient mice developed normal Th2 
responses after helminth parasite infection101.  
The cysteine proteases (Der p 1) in HDM can cleave epithelial tight junction proteins 
occludin and zonula occludens-1 (ZO-1), impairing an essential structural 
barrier102,103. Furthermore, Der p 1 can stimulate protease dependent release of 
TSLP and IL-25 from airway epithelial cells104. In addition, the proteases can 
inactivate lung surfactant proteins A and D (SP-A and SP-D), which are known to 
have important roles in host defense against bacteria105. Proteinase-activated 
receptor is activated by serine proteases in HDM resulting in an inflammatory 
response87. Therefore, HDM allergy is not only dependent on allergen-specific Th2 
responses but also on the activation of innate immune cells. Although, non-allergic 
individuals are also subject to the same level of HDM exposure, they do not develop 
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inappropriate immune responses. The explanation for this could be genetic 
susceptibility and/or the intensity of innate immune activation in allergic people106.  
 
1.1.6 Asthma pathogenesis 
Exposure to an allergen in susceptible individuals leads to allergen-specific IgE 
cross-linking high-affinity Fc receptors for IgE (FcεRs) on the surface of mast cells 
and basophils resulting in immediate release of leukotrienes, prostaglandins and 
histamine that can constrict airway smooth muscle and induce mucus secretion, 
while local chemokines recruit a number of other immune cells such as eosinophils, 
T cells and neutrophils107. Release of toxic granules from eosinophils can damage 
the epithelium. Also, some allergens with proteolytic activity such as HDM can 
damage epithelium directly by cleaving epithelial tight junction molecules108. The 
inflammatory cells also release Th2-associated cytokines such as IL-4, IL-5, IL-9 and 
IL-13 to enhance the allergic inflammation of the airways and lung (Fig. 1.1). Other 
than Th2 cells, T regulatory (T reg), Th17 and Th9 cells are associated with allergic 
responses to inhaled allergens79. 
Some allergens including HDM are reported to induce an allergic response through 
activation of innate immune receptors such as TLRs. The complex interactions of 
allergens, inflammatory cells and cytokines result in airway hyper-responsiveness 
and remodelling. Airway hyper-responsiveness caused by a stimulus like HDM leads 
to airway hyper-reactivity causing bronchoconstriction and inflammatory cell 
infiltration. Chronic exposure of the lungs to a stimulus can result in lung tissue 
remodelling- that involves changes in composition and structural organisation of the 
tissue109. 
 
	   	   Chapter	  1:	  Introduction	   	  
32	  
	  
 
Figure 1.1: Involvement of inflammatory cells in asthma. Early phase (occurs within minutes) 
mainly involve secretion of mediators by mast cells. However, in the late phase response 
(hours after allergen challenge) slow release of cytokines and chemokines occur by 
engagement of antigen presenting cells e.g. dendritic cells (DCs) with T helper (Th) type 2 
cells recruit other inflammatory immune cells i.e. eosinophils, T cells and B cells. Together 
the early and late phase products influence airway and lung endothelial, epithelial, 
fibroblasts and smooth muscle cells leading to wheezing, nasal blockage and mucus 
production. IL-Interleukin, TSLP-Thymic Stromal Lymphopoietin, TGF-β-Transforming 
Growth Factor, GM-CSF-Granulocyte Macrophage Colony Stimulating Factor. 
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1.1.7 Asthma therapies 
There is currently no cure for asthma and compliance with medication is not 
frequently maintained. Medication used in the clinic such as relieving 
bronchoconstriction with inhaled bronchodilators or oral cysteinyl leukotriene 
receptor 1 antagonists or corticosteroids is primarily to reduce symptoms.  
More specific therapies have been developed, for example, anti-IgE antibodies. 
Cross-linking of these receptors by FcεRI IgE release preformed mediators such as 
histamine, heparin and tryptase within 5 minutes and newly generated arachidonic 
acid such as leukotriene-D4, prostaglandin-D2 and cytokines such as tumour 
necrosis factor-α (TNFα) and IL-4110. The importance of IgE is seen during treatment 
of allergic disease with blocking recombinant humanised monoclonal antibodies to 
IgE, Omalizumab111,112. Omalizumab reduces the expression of high affinity IgE 
receptors on mast cells, basophils and dendritic cells by blocking IgE binding to high 
and low affinity IgE receptors110.  
Allergen-specific immunotherapy (SIT) involves repeated administration of an 
allergen and modifies cellular and humoral responses to allergens such as 
increasing T regs, IL-10 and transforming growth factor (TGF)-β production113,114. 
Anti-Th2 cytokine treatments have also been developed with limited clinical success. 
Combination therapies such as SIT with anti-cytokine antibodies may have a greater 
potential for success than single therapies. There is growing evidence that asthma 
treatments needs to be patient specific. Thus, there is still a clear need for research 
and development of more asthma therapies.  
Cytokines elevated in asthmatics such as IL-5, IL-13 and IL-4 are targeted for their 
therapeutic potential. High numbers of eosinophils are present in sputum and 
airways of asthmatics115. IL-5 (eosinophil recruiting cytokine) deficient mice have no 
eosinophilia in response to Th2 cell inducing stimuli, while baseline eosinophil counts 
remain normal116. Therefore, a number of human and mouse studies suggest that 
targeting eosinophil recruitment should provide therapeutic benefit for the treatment 
of asthma. However, blocking IL-5 with monoclonal antibodies (reslizumab) turned 
out to be effective (reduction in eosinophils and marked improvement in clinical 
symptoms) in only a specific group of asthmatics defined as poorly controlled, 
steroid-resistant eosinophilic asthma117. Lebrikizumab, an anti-IL13 monoclonal 
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antibody reduced the late asthmatic response in mild asthmatics by reducing 
markers of Th2 inflammation118. However, monoclonal antibodies directed against IL-
4 lack clinical efficacy while a variant of IL-4 that acts as an antagonist of IL-4Rα and 
IL-13Rα1 is more effective in reducing the frequency of asthma exacerbations in 
patients with single nucleotide polymorphisms in IL-4Rα119.  
 
1.1.8 Mouse models of asthma 
A variety of allergens, allergen doses and application routes have been used to 
induce allergic airways disease in mice to resemble common features of human 
asthma. The most common mouse strain used is BALB/c mouse that show a 
genetically determined tendency to develop allergic immune responses120,121. 
However, asthma features can be induced in C57BL/6 mice that is less susceptible 
to allergic airway disease122. Airway hyper-reactivity (AHR) can be assessed in 
murine models after exposure to metacholine, a bronchoconstrictory agent123. 
Although, chicken egg ovalbumin lacks clinical relevance, the OVA model is widely 
used as it provides the opportunity to study Th2 immune responses123. 
 
1.2 Respiratory bacteria: Streptococcus pneumoniae 
1.2.1 Epidemiology 
S. pneumoniae is a gram-positive α-haemolytic facultative anaerobic organism124. It 
commonly inhabits the upper respiratory tract especially in the nasopharyngeal as a 
commensal125. Asymptomatic carriers can transmit the organisms by coughing. Over 
90 serotypes have been recognised that colonise for weeks in adults or months in 
children126. However, if the colonisation spreads it can progress to a number of 
inflammatory diseases including pneumonia or systemic disease (Fig.1.2). The risk 
factors for nasopharyngeal carriage of S. pneumoniae are cigarette smoking, 
asthma, upper respiratory infections and immunocompromised health127. The 
incidence of IPD is also higher in children (<2 years), the elderly (>65 years) or in 
crowded environments such as day care centres and hospitals128.  
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Figure 1.2: Route for Streptococcus pneumoniae infection. Adapted from 129. Streptococcus 
pneumoniae is an airborne pathogen and can reside in the upper respiratory tract as a 
commensal. If it spreads, however, it can cause a number of inflammatory diseases such as 
pneumonia.  
 
1.2.2 Virulence factors 
S. pneumoniae has two main survival strategies- the invasive strains induce disease 
rapidly and spread efficiently, whereas the less invasive strains use surface adhesins 
and immune evasion strategies to allow long-term colonisation126. The bacterium has 
a number of virulence factors important in facilitating the disease process (Fig. 1.3). 
The capsule surrounding the bacterium is a critical virulence factor. 99% of IPDs are 
caused by encapsulated S. pneumoniae128. 91 different capsular polysaccharide 
types that are structurally and antigenically different have been identified, but the 
distribution of serotypes differs among geographic regions127. The capsule protects 
the bacteria from opsonophagocytosis by reducing the access of opsonins to the 
bacterial surface molecules and prevents mucosal clearance129. Below the capsule is 
the cell wall that consists of polysaccharides and lipoteichoic acid (LTA). The 
bacterium produces a 53-kDa pore forming toxin called pneumolysin during the 
logarithmic phase of growth130. This toxin binds to membrane cholesterol to form 
large pores130. Some activities attributed to pneumolysin are inhibition of ciliary 
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beating, inhibition of the phagocyte respiratory burst and induction of cytokine 
synthesis131. 
Three major groups of S. pneumoniae cell surface proteins identified are choline 
binding proteins, lipoproteins and proteins that are covalently linked to the bacterial 
cell wall by a carboxy-terminal sortase motif (LPXTG). S. pneumoniae also has a 
number of LPXTG-anchored proteins such as hyaluronidase (breaks down the 
hyaluronic acid component of extracellular matrix) and neuraminidase (cleaves N-
acetylneuraminic acid from glycolipids, lipoproteins and oligosaccharides)132. Choline 
binding proteins are anchored to the cell surface of S. pneumoniae. For example, 
autolysin (LytA) is an amidase that releases pneumolysin from the cytoplasm, 
pneumococcal surface protein A (PspA) that binds to lactoferrin to protect from 
bactericidal activity of apolactoferrin and interferes with the complement-mediated 
opsonisation and PspC that binds to immunoglobulin receptors and complement 
regulatory protein factor H to resist complement133. S. pneumoniae also has divalent 
metal ion binding lipoproteins such as pneumococcal surface antigen A, 
pneumococcal iron acquisition A and pneumococcal iron uptake A that are important 
in pneumococcal virulence131,132. S. pneumoniae depletion or mutations in all the 
virulence factors described above reduce virulence in animal models of pneumonia 
and bacteraemia. 
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Figure 1.3: A summary of pneumococcal virulence factors. Streptococcus pneumoniae 
synthesises several factors such as polysaccharide capsule, the cell wall and protein factors 
(pneumolysin, neuraminidase and hyaluronidase). Immunoglobulin (Ig), Complement protein 
(C3), Neuraminidase (nanA, B & C), Autolysin (LytA), Pneumococcal surface antigen A 
(PsaA), Pneumococcal adhesion and virulence A (PavA) and Enolase (Eno). Adapted 
from131.   
 
1.2.3 Host response to pneumococcal infection 
S. pneumoniae clearance requires both cellular and humoral immune responses as 
well as non-immune factors e.g. anatomical barriers and mucus. Intact respiratory 
epithelium is essential for bacterial clearance by providing mucociliary clearance and 
releasing soluble anti-microbial mediators. The early cellular host response to the 
bacterium is mediated by alveolar macrophages followed by neutrophils134 (Fig. 1.4). 
Interaction of S. pneumoniae LTA and pneumolysin with TLR2135 and TLR4136, 
respectively on airway epithelium or alveolar macrophages triggers anti-bacterial 
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cytokine production including CXCL1 (KC, murine homology of IL-8), IL-6, TNFα and 
IL-1β and co-operate to facilitate chemotaxis of neutrophils137,138. TNFα has an 
essential role in initial defense because its inhibition greatly enhances bacterial 
susceptibility139,140. Similarly, IL-8138 and IL-6141 deficiency are detrimental. The 
importance of neutrophils in pneumococcal elimination is seen in neutrophil depletion 
studies and in neutropenic patients who present increased infection and mortality142.  
TLR2 deficient mice produce significantly less neutrophil attracting chemokines 
(CXCL1 and CXCL2) and therefore show an increased susceptibility to bacterial 
infection143. More importantly, TLR2 deficient alveolar macrophages do not respond 
to LTA or S. pneumoniae143. Interestingly, TLR9 (associated with the recognition of 
bacterial DNA, CpG) deficient mice are highly susceptible to lethal infection144. CD4+ 
T cells also express TLR2 and TLR4 are likely to contribute to the adaptive immune 
response to pneumococcus145. Furthermore, patients with human immunodeficiency 
virus (HIV) are more susceptible to pneumococcal infection.  
Recognition of S. pneumonia by TLRs is not the only form of innate mediated 
recognition of S. pneumonia.  Opsonins such as complement proteins, acute phase 
proteins (C-reactive protein (CRP) and surfactant proteins) and antibodies directed 
against the capsule of the pneumococcus are essential for opsonophagocytosis146 
and activation of classical complement pathway via C1q.  
Mice deficient in other receptors, such as receptor for platelet-activating factor, 
SIGNR1 (C-type lectin), macrophage receptor with collagenous structure (MARCO, 
class A scavenger receptor), are highly susceptible to pneumococcal infection126. 
Antibodies to the capsule are important to protect against invasive pneumococcal 
disease. Pneumococcal vaccines aim to enhance antibody IgG to capsular 
polysaccharides and improve antibody/antibody-complement dependent 
phagocytosis. However, antibodies may not be primarily responsible for resistance to 
colonisation because COPD patients colonised with S. pneumonia did not have a 
lower concentration of antibodies to pneumococcal antigens147. The reduction in 
CD4+ T cell counts in human immunodeficiency virus infected individuals correlate 
with increased S. pneumonia infection148. CCL5 deficiency reduces IFN-γ producing 
CD4+ T cells and IgG2a and IgG1 antibodies in serum and these changes 
correspond with the transition from pneumococcal carriage to severe pneumonia149. 
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In addition, human pneumococcal carriage increases the proportion of IL-17A 
producing T cells and this cytokine enhances opsonisation of bacteria by alveolar 
macrophages150. Interestingly, patients with hyper-IgE syndrome that have mutations 
in STAT3 gene undergo recurrent S. pneumonia infections as a result of defective 
Th17 cell production151. However, some experiments have shown CD4 T cell 
numbers may adversely impact the cytokine network and survival during S. 
pneumonia induced pneumonia152. In contrast, CD8 T cells play an important role in 
improving survival from pneumococcal pneumonia153.   
 
 
Figure 1.4: Early immune response to bacterial infection in the airway. A) Bacterial 
components are recognised by alveolar macrophages and epithelial cells. B) These cells in 
turn secrete cytokines and chemokines to recruit C) neutrophils to site of infection. D) 
Neutrophil granule release promotes monocyte recruitment to help combat infection quicker. 
E) Macrophages also clear apoptotic neutrophils to promote resolution of infection. 
 
	   	   Chapter	  1:	  Introduction	   	  
40	  
	  
1.2.4 Vaccines and therapeutics 
Antimicrobial resistance by S. pneumonia has considerably increased worldwide 
particularly with the overuse of penicillin and erythromycin154. Resistance to 
macrolides, fluoroquinolones, and vancomycin are also reported126. The increased 
resistance to antibiotics highlights the importance of safe and effective vaccines.  
Introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 helped 
reduced the incidence of IPD, though the incidence of invasive disease caused by 
serotypes not included in the vaccine has arisen154. This led to the introduction of 
vaccines containing more pneumococcal serotypes e.g. PCV23. The PCV7 is part of 
the routine infant immunisation schedule and PCV23 is recommended for the 
elderly9.  
 
1.2.5 Mouse models of S. pneumoniae infection 
Animal models using S. pneumoniae isolates from human experimental colonisation 
studies have been used to define the host-pathogens factors that contribute to 
bacterial colonisation and spread131. Pneumonia due to S. pneumoniae has been 
studied largely by use of mouse models (Table 1.5). 
Table 1.5: Examples of Mouse Models of Streptococcus pneumonia. Adapted from158. i.n-
intranasal; i.t-Intratracheal.  
 
Route of 
infection 
Mouse 
Strain 
Pneumococcal 
serotype/strain 
Utility Reference 
i.n BALB/c Serotype 14 Therapy in neutropenic mice  
155 
i.n C57BL/6 Strain D39 Model of secondary bacterial 
pneumonia 
 
51 
i.t C57BL/6 Serotype 3 Drug efficacy and 
pharmacokinetics 
 
156 
Aerosol 
nebuliser 
CBA/J Serotype 28 Model of chronic obstructive 
pneumonia 
 
157 
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1.3 Cells of the innate immune response in allergic airway disease and 
bacterial infection 
1.3.1 Airway epithelial cells 
Airway epithelial cells not only form a physical barrier to environmental antigens, but 
also secrete a number of first line defence molecules to eliminate bacteria such as 
mucins (bind infectious agents), surfactant protein A and D (opsonises pathogen), 
antimicrobial peptides (defensins, cathelicidins and PLUNC that induce direct anti-
microbial action) and complement products to promote phagocytosis159. Epithelial 
cells express a range of receptors that enable them to respond to inhaled 
microorganisms and amplify host responses through the secretion of cytokines and 
chemokines.  
Antimicrobial peptides are polypeptides of 15-45 amino acids with a net positive 
charge. In the airways, antimicrobial peptides are mainly released by epithelial cells 
to opsonise and eliminate pathogens. Defensins, cathelicidins and short palate, lung 
and nasal epithelial clone-1 (SPLUNC1) are major antimicrobial peptide families. 
Deficiencies of these peptides impair antibacterial immunity. For example, deficiency 
in murine cathelicidin (cathelicidin-related antimicrobial peptide, CRAMP) increases 
gram-negative Klebsiella pneumoniae dissemination160. Mice deficient in β-defensin-
1 reveal a delay in Haemophilus influenzae clearance from the lungs161. SPLUNC1 
belongs to bacterial/permeability increasing protein family and regulates airway 
surface liquid volume162. SPLUNC1 deficient mice have increased mortality after 
Pseudomonas aeruginosa infection possibly as a result of increased neutrophil 
mediated immunopathology163. However, SPLUNC1 can be suppressed easily by 
direct insult of respiratory epithelial cells by PAMPs and IFN-γ 164. In OVA models of 
allergic airway disease, SPLUNC1 decreases and negatively correlated with 
numbers of eosinophils in the lung165. Furthermore, IL-13 inhibits SPLUNC1 
expression and M. pneumonia clearance166. Overall, antimicrobial peptides are 
important components of the innate immune system and allergic airway inflammation 
can suppress their activity167.  
In the healthy airways, 5% of airway epithelial cells are goblet cells; this increases to 
20-25% in asthma168. Goblet cells produce mucus that forms a semi-permeable 
barrier that enables the exchange of nutrients, water and gases and allow removal of 
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pathogens trapped in the mucus through the mucociliary escalator. However, 
overproduction of mucus can obstruct the airway lumen.  
HDM components and airway epithelial cell receptors such as Dectin-1 (binds beta-
glucan), TLR2 (beta-glucan), TLR4 (LPS) and platelet activated receptor-2 
(proteinases) interact to mediate allergic sensitisation, inflammation and 
remodelling169. HDM allergen, Derp 1 cleaves epithelial tight junction molecules such 
as occludin and increases penetration of allergens and pathogens into the lungs 170. 
In response to an allergen, epithelial cells secrete IL-33, IL-25 and TSLP. These 
epithelial derived cytokines induce activation of innate lymphoid cells and 
alternatively activate macrophages to produce IL-13 and IL-4 that in turn, polarise 
CD4+ T cells into Th2 phenotype. Moreover, murine allergic inflammation and AHR 
can be inhibited by antibodies directed against IL-33 receptor171 and IL-25172. 
 
1.3.2 Macrophages  
Macrophages are found in most tissues and assigned different names depending on 
which tissue they reside in: alveolar macrophages (airway/lung), kupffer cells (liver), 
microglia (nervous system) and langerhans cells (epidermis)173. In the lungs, alveolar 
macrophages and interstitial macrophages represent two major populations of 
macrophages based on their anatomical location. Alveolar macrophages line the 
surface of alveoli and are better phagocytes than interstitial macrophages. Interstitial 
macrophages reside in the space between alveolar epithelium and vascular 
endothelium and are better antigen presenting cells than alveolar macrophages174. 
Most lung resident macrophages are derived from bone marrow-derived monocytes. 
A study on murine macrophages shows that alveolar macrophages do not originate 
directly from blood monocytes, but require a lung macrophage intermediate175. 
However, this concept has been challenged recently and genetic fate mapping data 
defined a lineage of tissue macrophages that derive from the yolk sac176. 
Furthermore, in a recent paper, Guilliams et al found fetal monocyte transferred to 
the lung of neonatal mice acquired an alveolar macrophage phenotype dependent 
on GM-CSF and persisted for three months177. Taken together these data suggest at 
least two lineages of macrophages in mice; one derived from the yolk sac 
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(F4/80+CD11b-, most likely to constituent the majority of alveolar macrophages) and 
a second from the bone marrow (F4/80-CD11b+ macrophages).  
In a naïve mouse, 90-95% of airway cells are alveolar macrophages178 that express 
Ig receptors, complement receptors, mannose receptor and scavenger receptors to 
allow phagocytosis of pathogens and debris179. Phagocytosis can occur with or 
without opsonisation with complement, and subsequently release pro-inflammatory 
mediators such as IL-12 (activates natural killer cells), IL-8/CXCL1/CXCL2/TNF 
(recruits neutrophils), TNF/IL-1 (stimulates T cells) and lactoferrin/lysozyme 
(antimicrobial products)179. 
Macrophages become heterogenous and display various phenotypes depending on 
their microenvironment created by cytokines released by immune and lung structural 
cells. The diversity of macrophage functions has led to classification of macrophages 
into three groups: classically activated, alternatively activated (AAMs) or immune 
regulatory macrophages (Fig. 1.5)180.    
Classically activated macrophages, activated by IFN-γ and TNF or TLR ligands, 
have enhanced microbicidal activity. Cytokines (IL-6, IL-1 and IL-23) produced by 
these cells are an important part of host defense68. These macrophages will interact 
with T cells to give rise to Th17 cells that produce IL-17, a cytokine that is associated 
with increased neutrophil and Th1 cells recruitment (Fig. 1.6). In contrast to 
classically activated macrophages, AAMs have reduced anti-microbial capacity. The 
presence of IL-4 and IL-13 converts macrophages into AAMs to promote wound 
healing181 and this process is amplified by IL-33 and IL-25 produced by epithelial 
cells, macrophages and Th2 cells182. Innate immune cells, basophils and mast cells 
also produce IL-4. These macrophages produce less pro-inflammatory cytokines, fail 
to present antigens and are less efficient at killing intracellular pathogens such as 
Cryptococcus neoformans and Mycobacterium tuberculosis180,183. Also, treatment of 
influenza-infected mice with IL-4 significantly delays viral clearance184, although, 
AAMs are essential in helminth and nematode clearance.  
AAMs have some signature markers: Ym1 is a member of chitinase-like molecule 
family, induced by Th2 cytokines on macrophages182. Another marker, resistin-like 
molecule-α (Relmα also known as Fizz1) is induced by IL-13 in macrophages, 
epithelium and eosinophils182. Arginase 1 (Arg1) is induced by Th2 cytokines in  
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Figure 1.5: Macrophage phenotypes. A. Classically activated macrophages generate in 
response to T helper cell type 1 (Th1) cytokine, interferon-γ (IFN-γ) or tumour-necrosis factor 
(TNF) produced by antigen presenting cells (APCs). B. Exposure of macrophages to T 
helper type 2 (Th2) cytokines such as interleukin-4 (IL-4) produced by granulocytes or Th2 
cells. C. Regulatory macrophages arise in response to many stimuli and produce high levels 
of IL-10 to suppress immune responses. Adapted from180. 
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Figure 1.6: Macrophage interaction with T cell. Classically activated macrophages release 
interleukins 1, 6 and 23 to give rise to Th17 cells. Th17 cells produce IL-17, a cytokine 
associated with granulocyte recruitment. Adpated from180. 
 
macrophages and ultimately, results in fibroblast proliferation and collagen 
production185. In chronic murine schistosomiasis, arginase is induced in Th2 
granuloma associated macrophages important in enhancing granuloma size and 
fibrosis186. Therefore, activation of AAMs increases fibronectin/matrix associated 
proteins, promotes cell growth/tissue repair, increases parasite killing and enhances 
allergic immunity173. 
In summary, classically activated macrophages are induced by IFN-γ, expression of 
AAMs is induced by IL-4 and TLRs plus other stimuli e.g. immune complexes induce 
regulatory macrophages. The different macrophage populations express separate 
biomarkers, summarised in table 1.6.  
Alveolar macrophages are vital in host airway defence but their activation must be 
tightly controlled to prevent host-tissue damage. Alveolar macrophages express 
regulatory receptors to control their activation and pro-inflammatory cytokine 
secretion. IL-10 and TGF-β released by epithelial cells induce alveolar macrophages 
to express high levels of the myeloid inhibitory receptor, CD200R. This receptor 
interacts with CD200 expressed on the luminal side of airway epithelium. After the 
resolution of influenza, the intensity of CD200R expression is even higher than at 
homeostasis52. Inhibition of CD200R prevents S. pneumoniae induced sepsis in 
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influenza-infected mice by reducing early viral titres and subsequent damage of the 
lung51. Another macrophage inhibitory receptor is Triggering Receptors Expressed 
on Myeloid cells (TREM)- 2. TREM2 attenuates macrophage activation and reduces 
cytokine production in response to TLR agonists187. TREM2 reduces macrophage 
TLR responses via DAP12 and inhibits pro-inflammatory cytokine production in 
response to TLR ligands. IL-4 induced AAMs express TREM2 with reduced pro-
inflammatory cytokine production but enhanced phagocytosis of bacteria. 
Furthermore, IL-4 can induce TREM2 on resident peritoneal macrophages187.  
Similar to murine respiratory macrophages, humans have alveolar, bronchial and 
interstitial macrophages188 . However, humans also have pulmonary intravascular 
macrophages. As with murine monocytes, human monocytes are recruited to sites of 
inflammation by CCL2189 and growth factors like GM-CSF are involved in 
proliferation of both murine and human macrophages190. Human bone marrow 
derived macrophages constitutively express ST2191. Both murine and human 
alveolar macrophages suppress T cells in a similar manner e.g. inhibiting T cell 
response to IL-2192. Murine AAMs and regulatory macrophages produce greater 
amounts of IL-10 than classically activated macrophages. Alveolar macrophages 
from asthmatics release more IL-10 compared to non-asthmatic patients and 
corticosteroid treatment can further enhance IL-10 production193. Moreover, human 
IL-10 producing monocytes can differentiate into AAMs194. Bronchial macrophages 
from mild asthmatics have impaired phagocytosis and downregulation of phagocytic 
receptors CD16 and CD64195. A recent study has found that sputum macrophages 
from asthmatics did not express all the AAM markers such as Arg1, IL-10, IL-13, 
CD206 and CLEC10A, however, one AAM marker CCL17 was upregulated in mild 
steroid-naïve and moderate steroid-treated patients compared to non-atopic 
controls196.  
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Marker 
Classically activated macrophages 
IL-12 
iNOS 
CCL15 
CCL20 
CXCL9 
CXCL10, CXCL11 
TREM1 
Alternatively activated macrophages 
CCL18 
YM1 
RELMα 
CCL17 
IL-27Rα 
IGF1 
CCL22 
TREM2 
Regulatory macrophages 
IL-10 
LIGHT 
CCL1 
SPHK1 
Table 1.6: Biomarkers for three macrophage populations: classically activated 
macrophages, alternatively activated macrophages and regulatory macrophages. Adapted 
from180.  
 
1.3.3 Neutrophils  
Neutrophils (also known as polymorphonuclear cells or granulocytes) are essential 
effector cells in the innate immune system that kill microorganisms by phagocytosis, 
release of granules and neutrophil extracellular traps (NETs)197. They derive and 
mature in the bone marrow and, when terminally differentiated, they are released 
into the blood197. However, during an infection neutrophils readily migrate to 
inflammatory sites to clear the pathogens. Important mouse neutrophil 
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chemoattractants are KC/CXCL1, MIP-2/CXCL2 and IL-17, as well as other pro-
inflammatory cytokines such as TNF-α and IL-1β. Apoptotic neutrophils are removed 
by macrophages to prevent tissue damage. Neutrophil granules contain antimicrobial 
peptides, as shown in figure 1.7. NETs are extracellular structures composed of 
chromatin with antibacterial proteins from neutrophil granules and cytoplasm 
attached197,198, although, S. pneumoniae capsule reduces binding to NETs199. 
Individuals with marked neutrophil dysfunction, known as chronic granulomatous 
disease, suffer from recurrent infections including S. pneumoniae and Haemophilus 
influenzae200. Recently, it was shown that local cell death initiates interstitial 
neutrophil recruitment and clustering with leukotriene B4 (LTB4) playing a critical 
role201. 
Neutrophils are involved in the pathogenesis of asthma. Severe asthmatics in 
particular have greater sputum neutrophil counts202 and their airway smooth muscle 
cells upregulate neutrophil chemoattractant, IL-8203. Furthermore, another neutrophil 
recruiting cytokine IL-17 is increased in the airways of severe asthmatics204.  
 
 
 
Figure 1.7: Antibacterial properties 
of neutrophils. Neutrophils have 
three main groups of granules: 1. 
Primary granules develop first and 
contain myeloperoxidase, 2. 
Secondary granules lack peroxidase 
and lactoferrin 3. Tertiary granules 
are formed last.  
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1.3.4 Eosinophils  
Immune functions of eosinophils involve release of cationic proteins, antibody and 
complement mediated cytotoxicity, phagocytosis and recognition of pathogens and 
endogenous danger signals through TLRs and other pathogen recognition receptors 
(PRRs) to produce an efficient antibacterial response205. However, the quick decline 
in eosinophil numbers after bacterial infection suggests a very limited role. 
Resembling neutrophils, eosinophils have granules composed of cytotoxic cationic 
proteins and also store cytokines, chemokines and growth factors, available for rapid 
release206. Eosinophil derived TGFβ, matrix metalloproteinases (MMPs) and Th2 
cytokines effect tissue repair and remodelling206. Siglec F is member of the sialic 
acid binding Ig-like lectins and possibly the most specific marker for murine 
eosinophils207. In OVA-induced mice, anti-Siglec F antibodies reduce eosinophilic 
inflammation and AHR208. SiglecF (Siglec8 in humans), IL-5 receptor α and CCR3 
are the main receptors that define eosinophils209.  
Eosinophils are a common feature in allergic inflammation. Eosinophils are 
granulocytes that develop in the bone marrow with a half-life of 18 hours in the 
peripheral blood and recruited into tissues in response to appropriate stimuli e.g. IL-5 
and eotaxin209. In addition, molecules such as YM1 released by alternatively 
activated macrophages can recruit eosinophils. Eosinophils also secrete CCL17 and 
CCL22 to recruit Th2 cells to augment allergic airways disease210,211.  
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1.4 Pathogen recognition by Toll-like receptors 
The airways are constantly exposed to inhaled pathogens. Therefore, it is vital that 
the host detects pathogens efficiently and mounts a rapid anti-bacterial immune 
response. To do this innate immune cells express a number of PRRs that recognise 
pathogen-associated molecular patterns.  
The TLRs have evolved to detect conserved patterns on pathogens. So far twelve 
TLRs (TLR1-TLR9 and TLR11-TLR13) in mice and ten TLRs (TLR1-TLR10) in 
humans have been identified (Table 1.7). Ligands have been identified for all TLRs 
except for human TLR10, mouse TLR12 and mouse TLR13. All TLRs are found on 
the plasma membrane except TLR3, TLR7, TLR8 and TLR9 that are found 
intracellularly, in the endosome. The TLR signalling cascade is shown in figure 1.8.  
TLR activation can be regulated in a number of ways including release of anti-
inflammatory cytokines (IL-10 and TGF-β), reduced messenger RNA (mRNA) of 
TLRs, induction of cell apoptosis, increased micro RNA (miRNA), internalization of 
TLRs, cleavage and release of soluble TLR receptors or increased expression of 
intracellular TLR negative regulators 212,213. 
The triggering receptor expressed on myeloid cells (TREM) family consists of four 
myeloid transmembrane glycoprotein receptors and modulate TLR responses. 
TREM1 is expressed by monocytes/macrophages and neutrophils, associates with 
the immunoreceptor tyrosine-based activation motif (ITAM) containing signalling 
molecule DAP12 and stimulation of TREM1 induces cytokine production- IL-8 and 
MIP-1214. TREM1 is assigned the role of an amplifier of inflammation215. 
 
 
 
 
 
 
	   	   Chapter	  1:	  Introduction	   	  
51	  
	  
Toll-like 
receptor 
Toll-like receptor 
ligands 
Species 
Human                           Murine 
1:2 Bacterial lipoproteins ✓ ✓ 
2:6 Diacylated lipopeptide ✓ ✓ 
2 Lipotechoic acid (LTA) ✓ ✓ 
3 Viral dsRNA ✓ ✓ 
4 Lipopolysaccharide 
(LPS) 
✓ ✓ 
5 Flagellin ✓ ✓ 
7 Viral ssRNA ✓ ✓ 
8 Viral ssRNA ✓ ✓ 
9 Viral and bacterial 
Unmethylated CpG DNA 
✓ ✓ 
10 Unknown ✓ ✓ 
11 Toxoplasma profilin ✗ ✓ 
12 Toxoplasma profilin ✗ ✓ 
13 Bacterial RNA ✗ ✓ 
Table 1.7: Toll-like receptors and their ligands. 13 Toll like receptors have been identified 
that recognise various microbial components. Adapted from216. 
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Figure 1.8: Toll-like receptor (TLR) signalling pathway. Activation of TLRs by their ligands 
initiates a cascade of intracellular signalling molecules that result in activation of NF-κB and 
transcription of antimicrobial products. Marked in red are Intracellular negative regulators of 
TLR signalling molecules.  
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1.5 Aims and hypothesis 
In this thesis chronic HDM exposure will be used to induce murine allergic airways 
disease. In particular, the three week HDM exposure protocol that induces AHR, 
mucus hypersecretion, eosinophils, Th2 cells, upregulation of epithelial dervived 
cytokines such as IL-25 and IL-33 and airway remodelling 217. This model reflects 
HDM-induced allergic asthma, which is the most common cause of mild to moderate 
asthma; furthermore 40% of severe asthmatics are HDM allergic. Therefore, the 
murine model represents a clinically relevant model of human asthma. 
The hypothesis for this thesis is that the allergic lung mounts a defective anti-
bacterial response to S. pneumoniae and is therefore more susceptible to bacterial 
infection. This thesis addresses the possibility that asthma exacerbates bacterial 
infection rather than bacteria exacerbating underlying asthma.  
The aims are: 
1. To assess the susceptibility of the allergic lung to bacterial infection.  
2. To analyse the anti-bacterial immune response in mice with prior HDM 
induced allergic inflammation. 
3. To investigate features of alveolar macrophages after three weeks of HDM 
exposure. 
4. To evaluate bacterial susceptibility in a model where there is reduced allergen 
induced eosinophilic pathology (immune response).  
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CHAPTER 2 
2.0 Materials and Methods  
2.1 Laboratory animals  
Seventeen to nineteen gram or 6-8 weeks old female BALB/c mice were purchased 
from Harlan Olac Ltd, Bicester UK. ST2 deficient mice were originally generated and 
kindly provided by Professor Andrew McKenzie (University of Cambridge). All mice 
were maintained in specific pathogen free conditions at Bio Safety Level 2 and kept 
in accordance with institutional and UK Home Office guidelines.  
 
2.2 Streptococcus pneumoniae (D39) stock  
Wild type (WT) S. pneumoniae (serotype 2) strain D39 (NCTC 7466, National 
Collection of Type Cultures, London, UK). Bacteria were cultured at 37°C in 5% CO2 
on blood agar plates or in Todd-Hewitt broth (Sigma) supplemented with 0.5% yeast 
extract (OXOID) (THY broth) to an OD600 of 0.2 (approximately 2x10^8 CFU/ml) 
and stored at -80°C in 10% glycerol as single-use aliquots. Exact inoculum colony 
forming units (CFU) used in each experiment and the recovered tissue CFU were 
determined by manually counting colonies of serial tenfold dilutions plated on 
Columbia agar supplemented with 5% defibrinated horse blood.  
 
2.3 Animal allergy and infection models  
2.3.1 Murine allergic airway disease induction   
BALB/c mice were anaesthetised with isoflurane and intranasally (i.n.) inoculated 
with 15µg HDM (Chapters 3 & 4: Greer, Lenoir, N.C, USA, batch number 
XPB82D3A2.5, lot: 151176- Derp 1 149.02 µ/vial, Protein 4.29 mg/vial, 125 
Endotoxin EU/vial and Chapter 5: Greer, Lenoir, N.C, USA, batch number 
XPB70D3A2.5, lot: 213051- Derp 1 145.56mcg/vial, Protein 2.87 mg/vial, endotoxin 
31.25 EU/vial) extract dissolved in phosphate buffered saline (PBS) sterile or PBS 
alone for controls for 3 times/week for 3 weeks.  
2.3.2 Respiratory bacterial challenge  
S. pneumoniae (serotype 2) strain D39 was diluted in endotoxin free sterile PBS and 
administered i.n in a volume of 50µl to mice held in an upright position. Groups were 
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followed daily for illness. Mice were harvested at predetermined time points post 
infection by injection of 3 mg pentobarbitone and exsanguinated via the femoral 
vessels.  
2.3.3 Recombinant murine chemokine administration  
To restore anti-bacterial immunity 1µg of recombinant murine CXCL1 (KC, 
Peprotech; Cat. No: 250-11), recombinant murine CXCL2 (MIP-2, Peprotech; Cat. 
No: 250-15) or recombinant murine CCL2 (MCP-1, Peprotech: Cat. No: 250-10) was 
given i.n per mouse reconstituted in 20µl sterile PBS.  
 2.3.4 Intranasal PKH26-PCL dye administration 
Mice were given intransal administration of 50µl of 10µM PKH26 red fluorescent cell 
linker kit for phagocytic cell labeling (PKH26-PCL) from Sigma that is ingested by 
phagocytic cells in the airways218. PKH26-PCL (Sigma) labels cells with phagocytic 
capabilities through ingestion of dye micro-aggregates. We administered dye to 
BALB/c mice 72 hours before the first HDM exposure and then exposed the lungs to 
three weeks of 15µl PBS or 15µg HDM (3 times a week).  
 
2.4 Lung Histology  
2.4.1 H&E and PAS staining of lung tissue  
One right lung lobe of BALB/c mouse was placed in formalin for 24 hours then 
transferred into 70% ethanol or industrial methylated spirit (IMS) and 4 micron 
sections were stained with Haematoxylin and Eosin (H&E) or Periodic acid-Schiff 
stain (PAS). The H&E and PAS stainings were performed by Lorraine Lawrence, 
NHLI, Imperial College, UK.  
Mucus scoring: mucus-containing cells were counted on PAS stained sections using 
an arbitrary scoring system. Goblet cells in the airway epithelium were quantified 
according to the following scoring system; 0 score = <0.5%, 1 score = 5-25%, 3 = 
25-50%, 3 = 50-75% and 4 = >75% of positive purple stained cells. The total scores 
for each section were divided by the number of airways examined and expressed as 
mucus index in arbitrary units.  
2.4.2 Immunohistochemistry 
A. CXCL1: Paraffin-embedded lung sections were incubated with goat anti-mouse 
CXCL1 IgG (15µg/ml, R&D systems Cat: AF-453-NA) with incubation for 1 hour at 
room temperature. An avidin/biotin horseradish peroxidase cell staining kit from R&D 
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systems (CTS008) was used with diaminobenzidine to give a brown-colored product 
at the site of CXCL1 presence. Subsequently, sections were counter-stained in 
haematoxylin, mounted and photographed using a light microscope.  
B. RELMα and Ym1: Paraffin-embedded sections lung sections were incubated with 
goat anti-mouse RELMα (1µg/ml, R&D systems, Cat no: AF1523) or YM1 (1µg/ml, 
R&D systems, Cat no: AF2446) and detected with anti-goat horseradish peroxidase 
(HRP)- 3,3’-diaminobenzidine tetrahydrochloride (DAB) cell staining kit (R&D 
systems, CTS008). Sections were counter stained with haematoxylin, mounted with 
DPX and photographed using a light microscope.  
 
2.5 Sample recovery and cell preparation of BAL and lung tissue  
Bronchoalveolar lavage (BAL), lung tissue and blood were harvested. Blood clotting 
was prevented by heparin (1:10 dilution).  
1. Chapter 3: BAL was obtained by inflating the lungs of each mouse 3 times 
with 1.5ml 1mM ethylenediaminetetraacetic acid (EDTA) in Hank’s buffered 
salt solution (HBSS) and placed in sterile tubes on ice. BAL was centrifuged 
for 5 minutes at 1200 RPM and the supernatant removed and stored at -80°C 
for analysis of cytokines by ELISA. 
2. Chapter 4 & 5: BAL was obtained by inflating the lungs of each mouse 3 times 
with 1.2ml 1mM EDTA in HBSS and placed in sterile tubes on ice. This was 
repeated one more time, however, supernatant was only stored from the first 
wash. Cells from both washes were used for counting and flow cytometry 
staining. BAL was centrifuged for 5 minutes at 1200 RPM and the supernatant 
removed and stored at -80°C for analysis of cytokines by ELISA. The number 
of BAL washes was increased in chapters 4 and 5 to increase the total cell 
numbers recovered from the airways for multiple flow cytometry staining 
panels. 
The pellet was re-suspended in RPMI-1640 supplemented with 10% fetal calf serum 
(FCS) and penicillin/streptomycin (P/S) at a final concentration of 1x10^6 cells/ml for 
fluorescence-activated cell sorting (FACS) analysis.  
Lung tissue was finely minced and digested with dispase (0.4 Wunsch units/ml 
Roche) and DNase (50µg/ml of 100mg DNase I 10104159001 Roche 1:2000) with 
shaking for 30 minutes at 37°C. This digested preparation or whole lung tissue was 
disrupted to a single cell suspension by passage through a 70µM sieve (BD 
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labware/falcon, USA Cat. No: 352350). The cell suspension was subsequently spun 
for 5 minutes at 1200 RPM and red blood cells lysed by re-suspending pellets in 
ACK buffer (0.15M ammonium chloride, 1M potassium hydrogen carbonate and 
0.01mM EDTA, pH7.2) for 3 minutes at room temperature (RT) before centrifugation 
for 5 minutes at 1200 RPM and washing in RPMI. Cell viability in all tissues was 
assessed using Trypan Blue exclusion and subsequently re-suspended in 
RPMI+FCS+P/S to a final concentration of 1x10^6 cells/ml. 
2.5.1 Analysis of bone marrow mobilisation of neutrophils  
Femurs were isolated from BALB/c mice and the bone marrow was flushed with 
HBSS (1x), HEPES 30mM, EDTA 15mM using a 23G needle. Any clumps were 
resuspended using a 21G needle and span at 1200rpm for 5 minutes. Red blood 
cells were lysed using 3ml 0.2% NaCl followed immediately by 3ml 1.6% NaCl and 
made up to 20ml with RPMI and 0.1% BSA. Cell viability was assessed using Trypan 
Blue exclusion and subsequently re-suspended in RPMI+0.1%BSA. Cells were 
FACS stained for neutrophils as described in section 2.7.1.  
 
2.6 Determination of bacterial load in blood, BAL and lung  
Airway, lung and blood bacterial titres were determined by serial dilution of 20µl 
aliquots from single cell suspensions of each tissue in sterile PBS. Serial dilutions 
were plated on Columbia blood agar with 5% supplemented with 5% defibrinated 
horse blood (TCS Bioscience HB034) and incubated overnight at 37°C in 5% CO2. 
The total CFU per tissue was determined manually by counting bacterial colonies on 
the plates (number of colonies x dilution factor x original cell suspension volume).  
 
2.7 Flow cytometric analysis  
2.7.1 Extracellular antigen analysis  
Cells were stained for surface markers and analysed by flow cytometry. A minimum 
of 2x10^5 or a maximum of 1x10^6 BAL or lung derived cells were stained using 
various combinations of FITC, PE, PerCP-Cy5.5, PE-Cy7 and APC antibodies. All 
antibodies (Table 2.1) were diluted in PBS containing 1% Bovine serum albumin 
(BSA) with 0.5% sodium azide [PBA]. Cells were stained for 30 minutes on ice, 
washed with PBA and spun for 2 minutes at 2000 RPM. After washing, cells were 
fixed for 20 minutes at RT with 2% formaldehyde/PBS. Cells were then washed in 
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PBS and re-suspended in a final volume of 200µl PBA. Data acquired on a BD FACS 
CANTOII (BD) or Fortessa II (BD) and analysed on FlowJo software. Forward scatter 
and side scatter gates were used to exclude debris on organ homogenates.  
Product 
name 
Company Catalogue 
number 
Clone Stock 
Concentration 
Dilution  
CD11b eBioscience 45-0112-82 M1/70 0.2mg/ml 1:400 
TLR2 eBioscience 51-9021 6C2 0.2mg/ml 1:200 
CD3e eBioscience 25-0031-82 145-2C11 0.2mg/ml 1:200 
CD4 eBioscience 45-0042-82 RM4-5 0.2mg/ml 1:200 
CD8a eBioscience 17-0081-82 
11-0081-85 
53-6.7 
53-6.7 
0.2mg/ml 
0.5mg/ml 
1:200 
1:100 
γδ TCR eBioscience 553177 GL3 0.5mg/ml 1:100 
IL-17 eBioscience 17-7177-81 eBio17B7 0.2mg/ml 1:100 
IL-9 eBioscience 50-8091 RM9A4 0.2mg/ml 1:100 
TNFα eBioscience 17-7321-82 MP6-XT22 0.2mg/ml 1:100 
IFN-γ eBioscience 25-7311-82 XMG1.2 0.2mg/ml 1:100 
F4/80 eBioscience 25-4801-82 
12-4801-82 
BM8 
BM8 
0.2mg/ml 
0.2mg/ml 
1:200 
1:200 
CD11c eBioscience 25-0114-82 
11-0114-82 
12-0114-82 
N418 
N418 
N418 
0.2mg/ml 
0.5mg/ml 
0.2mg/ml 
1:200 
1:100 
1:200 
CD200R eBioscience 17-5201-82 OX110 0.2mg/ml 1:200 
ST2L mdbioproducts 101001F DJ8 0.5mL 1:100 
TREM1 R&D systems FAB1187A 174031 10µg/ml 1:100 
TREM2 R&D systems FAB17291P 237920 25µg/ml 1:100 
Ly6G BD Pharmingen 551460 1A8 0.5mg/ml 1:100 
Siglec F BD Pharmingen 552126 E50-2440 0.2mg/ml 1:200 
TRAF6 Abcam Ab33915 - - 1:200 
IRAK Abcam ab238 - 0.5mg/ml 1:200 
Chicken 
anti-rabbit 
Secondary 
Abcam Ab6825 - 1mg/ml 1:500 
Table 2.1: List of antibodies used in experimental work in this thesis.  
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In most experiments (all experiments in chapter 4 and 5), dead cells were excluded 
using a fixable near-IR dead cell stain kit for 633 or 635nm excitation (Invitrogen; 
L10119).  
Fluorescence minus one (FMO) control was included for each fluorescent marker, 
the expression of a particular marker was calculated by subtracting FMO 
fluorescence values from fluorescent antibody levels.   
2.7.2 Intracellular cytokine expression  
To detect intracellular cytokines, 1x10^6 cells/ml were incubated with 50ng/ml 
Phorbol-12myristate-13-acetate (PMA), 500ng/ml ionomycin (Calbiochem, 
Nottingham, UK) and 10μg/ml brefeldin A for 3 hours at 37°C. Cells were then 
stained for extracellular antigens such as anti-CD4-PerCP-Cy5.5, anti-γδ T cell 
receptor (TCR)-FITC and anti-CD3-PE-Cy7 (all eBioscience) and fixed as described 
in 2.7.1. After permeabilisation with PBS containing 1% saponin/ 1% BSA/ 0.05% 
azide (saponin buffer) for 10 minutes: 
A. Cytokine staining: Cells were stained with anti-IL-17-APC (eBioscience) 
diluted 1:50 in saponin buffer for 30 minutes. Cells were then washed once in 
saponin buffer and once in PBA.  
B. Intracellular protein staining (IRAK and TRAF-6): After permeabilisation in 
saponin buffer for 15 minutes, cells were incubated with primary antibodies 
rabbit polyclonal anti-IRAK (1:200 dilution, Abcam, ab238) or rabbit 
monoclonal anti-TRAF-6 (1:200 dilution, Abcam, ab33915) for 16h at 4°C 
followed by 2 washes and then incubation with secondary antibody chicken 
anti-rabbit-FITC (1:500 dilution, Abcam, ab6825) for one hour.  
Data was then acquired as described in section 2.7.1.   
 
2.8 Cell Sorting by flow cytometry 
BAL was obtained by inflating the lungs of each mouse multiple times with 1.2ml 
1mM EDTA in HBSS and placed in sterile tubes on ice. The cell suspension was 
subsequently spun for 5 minutes at 1200 RPM and red blood cells lysed by re-
suspending pellets in ACK buffer (0.15M ammonium chloride, 1M potassium 
hydrogen carbonate and 0.01mM EDTA, pH7.2) for 3 minutes at room temperature 
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(RT) before centrifugation for 5 minutes at 1200 RPM and washing in RPMI. Cells 
were then stained with 1µl in 1ml of fixable near-IR dead cell stain kit for 633 or 
635nm excitation (Invitrogen; L10119) in PBS incubated for 20-30min at 4°C. After 
washing the cells in PBS: 
1. Dye positive cells were resuspended in RPMI (no FCS+P/S) and ready to run for 
sorting. 
2. Cells were stained with CD11b and CD11c in RPMI for 30 minutes at 4°C and 
then washed in RMPI before cell sorting. 
2.8.1 Sorting of airway cells dyed with PKH26-PCL red fluorescent cell 
linker 
The PKH26 red fluorescent cell linker kit for phagocytic cell labelling (PKH26-PCL) 
from Sigma was used to label airway macrophages. 
An example of cell sorting profile of airways that received no dye (unstained)  
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An example of cell sorting profile of PBS exposed airways that received dye  
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An example of cell sorting profile of HDM exposed airways that received dye  
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2.9 Cytokine detection using ELISA  
TNF (BD or eBioscience), CXCL1 (KC, R&D systems), CXCL2 (MIP-2, R&D 
systems), CRP (R&D systems), SP-D (Uscn Life Science Inc. SEB039MU), IL-17A 
(eBioscience), IL-33 (eBioscience) and IL-6 (eBioscience) in BAL fluid were 
quantified using Duoset ELISA kits and following manufacturer’s instructions. 
Microtiter plates (Nunc, Roskilde, Denmark) were coated with 100µl of capture 
antibody diluted in the recommended buffer and incubated according to the 
manufacturer’s protocol. After 3-5 washes with PBS containing 0.5% Tween 20, 
plates were blocked with 200µl of recommended reagent diluent and left for 1 hours 
at RT. Samples and standards (diluted in reagent diluent) were then incubated for a 
further 2 hours at RT. After 3-5 washes, bound cytokine was detected using 
biotinylated antibodies with avidin-HRP followed by tetramethylbenzidine (TMB). 
Optical densities were read at 450nm using 570nm as a reference. The mean optical 
density of blank wells (no cytokine) was subtracted from the results obtained for 
samples and standards. A standard curve was used to calculate the concentration of 
cytokine in each sample using Excel or GraphPad Prism 5 software. 
 
2.10 Isolation of mRNA and real-time PCR  
A. mRNA: Total lung RNA was extracted using RNeasy Mini kit (QAIGEN, UK), 
reverse transcribed into complementary (c) DNA (SuperScript III Reverse 
transcriptase, Invitrogen, Cat. No: 18080), and then amplified using specific primers 
for the TLR negative regulators tested. All values were normalised against the 
expression of 18S and then to a control sample (PBS) using ABI7900HT (Applied 
Biosystems, CA) sequence detection system and software. The primers for the 
genes of interest were purchased from Applied Biosystem (all TaqMan probes): Toll 
interacting protein (Tollip) (Mm00445841), Irakm (Mm00518541), A20 
(Mm00437121), Triad3A (Mm012005634), Ym1 (Mm00657889), Relmα 
(Mm00445109), Arg1 (Mm00475988), Tlr2 (Mm00442346), Tlr3 (Mm01207404), Tlr4 
(Mm00445273), Tlr9 (Mm00446193), Irak1 (Mm01193538) and Traf6 
(Mm00493836). 
B. miRNA: miRNA was extracted and detected using the TaqMan MicroRNA Cells-
to-CT kit (Ambion, Life technologies, 4391848) manufacturer’s instructions. TaqMan 
MicroRNA assays were used to detect mmmu-miR-146b-5p (Applied Biosystems, 
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001097). All values were normalised against the expression of snoRNA202 (001232) 
and then to a control sample (PBS) using ABI7900HT (Applied Biosystems, CA) 
sequence detection system and software.  
 
2.11 Western blot 
SPLUNC1 was detected by western blotting. Briefly, all samples were 
electrophoresed by reducing sodium dodecyl sulfate-polyacrylamide gels and 
electroblotted onto nitrocellulose membranes. Membranes were blocked in PBS 
containing 5% milk and 0.1% Tween-20 for 2h at RT and incubated with sleep anti-
mouse PLUNC (SPLUNC1; 1µg/ml, R&D systems) diluted in 5% milk/PBS/0.1% 
Tween-20, overnight at 4°C. After three washes of 15 min in PBS/0.1% Tween-20, 
membranes were incubated with Donkey anti-sheep IgG-HRP (1:1000 dilution, R&D 
systems) and detected using ECL chemiluminescent kits (Pierce, Rockford, IL).  
 
2.12 Genotyping 
BALB/c wild-type controls and ST2 deficient mice were genotyped using 
REDExtract-N-Amp Tissue PCR kit (Sigma). Primers used for genotyping were 
Primer 1 854 TGT TGA AGC CAA GAG CTT ACC and Primer 2 TTG GCT TCT TTT 
AAT AGG CCC. 2% agarose gel was used with hyperladder 100bp Plus (Bioline Bio-
33071) and SYBR Safe DNA gel stain was used for visualization of DNA. Wild-type 
band were 300bp band, whereas the homozygous ST2 knock out displayed no band 
on the gel.  
 
2.13 Statistics  
GraphPad Prism software was used for all statistical calculations. Statistical test 
used was Mann-Whitney compared to PBS controls (or as indicated in the figure). 
Data presented as box and whisker plots show median and range of data. ELISA 
data is shown as mean ± standard deviation (SD) and unpaired two-tailed t test was 
used. p values < 0.05 were considered significant (* p<0.05, ** p<0.01, ***p<0.001). 
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CHAPTER 3 
3.1 Introduction  
3.1.1 Asthma and S. pneumonia 
There is no life long immunity against IPD through natural infection or vaccination. 
Moreover, individuals with immunocompromised lungs are more likely to suffer from 
S. pneumoniae induced pneumonia. As discussed earlier, clinical data show that 
asthmatics are more susceptible to bacterial infections and present defective anti-
bacterial immune responses. For example, HDM-sensitised children have reduced 
IgG1 antibody levels for PspC, which is a surface protein on S. pneumonia219.  
In contrast, murine models of allergic airways disease using the atypical allergen 
OVA for sensitisation and challenge show no defect in bacterial clearance220-222. 
Kang et al assessed development of pneumococcal pneumonia in OVA sensitised 
mice using bioluminescent S. pneumoniae strain (A 66.1 serotype 3)220 and 
concluded that allergic airways disease actually reduced susceptibility to 
pneumococcal pneumonia. However, the experimental protocol used by Kang et al 
did not significantly increase Th2 associated cytokines IL-4, IL-13 and IL-5 (a 
common feature of allergic response) in the OVA sensitised mice compared to the 
control group. In addition, the authors did not present data on cellular infiltrate after 
OVA to validate their allergic airways disease protocol. Another study using OVA and 
S. pneumonia (serotype and dose unknown) show bacterial infection after OVA 
sensitisation but before OVA challenge suppresses allergic airways disease possibly 
due to an increase in Foxp3+ T regulatory cells. Similarly, treatment with ethanol 
killed S. pneumonia or administering the bacteria before OVA sensitisation and 
challenge suppresses allergic airway disease221.   
The main difference between these studies and the allergic and bacterial protocols to 
be used in our studies is the use of a clinically relevant allergen, HDM. OVA 
sensitisation requires intraperitoneal priming while HDM will be administrated 
intranasal (mimicking the natural route of exposure) and does not require peritoneal 
sensitisation with aluminum hydroxide (Th2 skewing adjuvant). Therefore, allergic 
inflammation will result after mucosal sensitisation within the lungs. Furthermore, 
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HDM replicates the environment created by common allergens better than OVA, 
which contains no proteolytic activity or TLR ligands.  
 
3.1.2 Prior lung inflammation alters susceptibility to pneumonia 
It is not simply asthma that increases susceptibility to S. pneumonia 16. Clearance is 
also hampered following influenza infection 51,52,223 and chronic COPD224. Many 
reasons for enhanced susceptibility of influenza-infected mice to bacterial 
pneumonia have been identified. For example, influenza virus neuraminidase 
removes sialic acid from the lung exposing receptors for bacterial adherence225. 
Influenza enhances the anti-inflammatory cytokine IL-10226,227, upregulates platelet-
activating factor receptor228, reduces tracheal mucociliary rate229, type I interferon 
mediated impaired production of CXCL1 and CXCL2 after bacterial infection230 and 
induces alternative activation of lung macrophages231. Clearly, a prior lung infection 
can alter innate immune responses to a subsequent pathogen and the effect may 
last for several months53. In this chapter the impact of HDM on the ability to clear S. 
pneumoniae and the mechanisms responsible for any modifications are elucidated 
based on our knowledge of influenza infection.  
 
3.1.3 Hypothesis and Aims 
To date many studies have investigated the possibility that bacteria exacerbate 
asthma, but only a handful considers that asthma may cause a bacterial 
exacerbation. Our hypothesis is to study how asthma affects immune responses to 
inhaled bacteria. Therefore, the aim is to elucidate the innate anti-bacterial immune 
mechanisms that are modified following HDM exposure and that subsequently 
impact on control of respiratory bacteria. The specific aims were: 
1. To examine the response of the allergen exposed lung to S. pneumoniae. 
2. To assess the molecular and functional alterations that occur in anti-
pneumococcal immunity in the allergic lung. 
3. To examine alteration of immune potentiators and negative regulators of 
innate immunity. 
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Data from this chapter was published in the journal of Mucosal Immunology232.  
 
3.2 Results 
3.2.1 HDM exposure induces allergic airway disease 
The ability of HDM allergen to induce experimental asthma in BALB/c mice was first 
examined.  50-85% of asthmatics are HDM allergic and it is therefore a clinically 
relevant allergen to use that unlike OVA, does not require intraperitoneal priming82. 
HDM naturally contains LPS. The Greer HDM used in this thesis has a low LPS 
content (0.1-1ng) per 25µg dose, which is far lower than the dose of LPS (100ng) 
required to promote Th2 responses in OVA models233. We first ascertained that the 
standard hallmarks of airway disease were present by sampling prior to bacterial 
challenge. Intranasal administration of HDM three times a week for three weeks (Fig. 
3.1A) resulted in increased mucus production and increased airway and lung 
cellularity and eosinophils as described before234. 
HDM-induced airway inflammation was monitored by histology and BAL & lung 
eosinophilia. HDM exposure resulted in significantly increased cellularity in the 
airways and lungs compared to PBS controls in H&E stained lung sections and by 
enumerating total viable cell counts (Fig. 3.1B & C). Similarly, only the HDM 
exposed group produced mucus as seen in PAS stained lung sections (Fig. 3.1B) 
with significantly increased eosinophil numbers in BAL (p=0.0079) and lung 
(p=0.0079) (Fig. 3.1D). Furthermore, three weeks of HDM exposure significantly 
increased airway and lung CD4+ T cells (Fig. 3.1E).  
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Figure 3.1: Induction of allergic airway inflammation after repeated intranasal HDM 
administrations into the airways. (A) Experimental design: BALB/c mice were inoculated 
intranasal with 15µg of house dust mite (HDM) extract three times a week for 3 weeks and 
subsequently harvested on day 0 (72 hours post final HDM exposure). As a control we 
included BALB/c mice intranasal exposed to phosphate-buffered saline (PBS) instead of 
HDM. (B) Histologic sections of lungs were stained with haematoxylin and eosin (H&E) and 
periodic acid Schiff (PAS) to determine lung cellularity and the degree of mucus production 
and goblet cell hyperplasia and analysed by light microscopy (original magnification x10). 
Pictures show representative samples of five per group from one experiment and are 
representative of two independent experiments. (C) After 3 weeks of HDM challenge, the 
total viable bronchoalveolar lavage fluid (BALF/airway) & lung cell count determined using 
trypan blue exclusion.  (D) The number of CD11b+SiglecF+ eosinophils and (E) CD4+ T cells 
were discriminated in airway and lung by flow cytometry. Data presented as box and whisker 
plots showing the median and minimum to maximum range. Data representative of five per 
group and are representative of three independent experiments. *P<0.05; ** P<0.01. 
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3.2.2 HDM exposure prior to S. pneumoniae infection reduced bacterial 
clearance 
At 72 hours after the final allergen challenge, S. pneumonia was administered 
intranasal (Fig. 3.2A) and the lung and BAL sampled after 4, 48 and 96 hours. 100% 
of HDM exposed group had bacteria in the BAL and lung compared to 0% of PBS 
controls 48h post infection (Fig. 3.2B). The increased bacterial titres in the HDM 
group correlated with the increased numbers developing bacteraemia. The interval 
between 48 and 96 hours post infection seemed to be the most crucial in 
determining whether the groups could recover from the infection or develop 
bacteraemia. The bacterial titres at the 96 hours post infection is not shown as some 
had to be culled in the HDM/S. pneumonia group and so the results were biased 
towards survivors. 40% of HDM exposed mice were sacrificed at 96 hours after 
infection (n=5-6 of two independent experiments).   
Allergen exposure typically induces mucus by increased secretion of mucins by 
goblet epithelial cells. Despite, cessation of HDM exposure mucus production 
remained. Strikingly, following S. pneumonia infection, mucus production actually 
increased as reflected in histology (Fig. 3.3A) and mucus scores (Fig. 3.3B). This 
was not observed in PBS infected group and is therefore not a feature of bacterial 
infection alone.  
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Figure 3.2: Allergic airway inflammation induces exacerbation of lung Streptococcus 
pneumoniae (S.pn) infection. (A) Experimental setup of house dust mite (HDM)-induced 
allergic airway inflammation and bacterial (Streptococcus pneumoniae) infection in BALB/c 
mice. BALB/c mice were inoculated intranasal with 15µg of house dust mite (HDM) extract in 
15µl phosphate-buffered saline (PBS) or 15µl PBS alone three times a week for 3 weeks 
and subsequently infected with 1x106 CFU of Streptococcus pneumoniae (D39 strain) 
harvested on day 0 (72 hours post final HDM exposure). (B) Colony forming units (CFUs) 
were calculated using serial dilutions of single cell suspensions of each sample and plated 
on blood agar plates. Bacterial titres were measured at 0, 4 and 48 hours post infection in 
bronchoalveolar lavage fluid (BALF/airway), lung & blood (ND= not detected). Data 
representative of five per group and are representative of 2 independent experiments at 4 
hours and 4 independent experiments at 48 hours. 
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Figure 3.3: Enhanced mucus production in HDM-sensitised mice is exacerbated 
following bacterial infection. (A) Histologic sections of lungs were stained with periodic 
acid Schiff (PAS) to determine the degree of mucus production (arrows) and goblet cell 
hyperplasia analysed by light microscopy (original magnification x10). Pictures show 
representative samples of five per group from one experiment and are representative of two 
independent experiments. (B) Mucus-containing cells were counted on PAS stained sections 
using an arbitrary scoring system. Goblet cells in the airway epithelium were quantified 
according to the following scoring system; 0 score = <0.5%, 1 score = 5-25%, 3 = 25-50%, 3 
= 50-75% and 4 = >75% of positive purple stained cells. The total scores for each section 
were divided by the number of airways examined and expressed as mucus index in arbitrary 
units. S.pn=S. pneumonia  
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3.2.3 Blunted cell recruitment in HDM exposed mice after bacterial infection 
compared to PBS controls 
The inflammatory response to bacteria in allergic lungs was measured next. Total 
cellularity measured 72 hours after final HDM exposure but prior to bacterial 
infection, was significantly increased in the airways and lung of HDM exposed group  
(0 hour after infection) compared to PBS controls (Fig. 3.4). In contrast, 48 & 96 
hours after infection, the total viable cell numbers decreased in the airways of HDM 
exposed mice (Fig. 3.4A). This is depicted more clearly as percentage of baseline- 
total cell count at time of infection (0 hour) (Fig. 3.4B). Total cellularity in the lungs of 
PBS exposed mice increased significantly 48 hours (p=0.0079) post infection; while 
there were no changes in the HDM exposed mice that already possessed high cell 
numbers (Fig. 3.4C & D). Since the numbers of cells in the HDM groups are similar 
in the lung yet the number recruited in the airspace is blunted in the allergen 
exposed groups 48 hours post infection this may suggest impaired recruitment of 
cells from the lung to the airways or increased apoptosis of cells in the airway. 
Flow cytometric analysis was used to determine the cellular phenotype in the 
airways and lung in response to HDM exposure. Prior to bacterial infection the 
airway and lung was dominated by eosinophils (Fig. 3.5A & B) and CD4+ T cells (0 
hour post infection) in HDM exposed mice (Fig. 3.5C & D).  Eosinophils were absent 
in the PBS group prior to bacterial infection and CD4+ T cells absent or low, following 
bacterial infection the number of both populations decreased. Therefore, the reduced 
cellularity from baseline in the airspaces can be explained by a reduction in 
eosinophils and CD4+ T cells in both the airway and lung.  
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Figure 3.4: Total airway and lung cell counts in PBS or HDM exposed group after 
Streptococcus pneumonia (S.pn) infection. BALB/c mice were inoculated intranasal with 
15µg of house dust mite (HDM) extract in 15µl phosphate-buffered saline (PBS) or 15µl PBS 
alone three times a week for 3 weeks and subsequently infected with 1x106 CFU of 
Streptococcus pneumoniae (D39 strain) harvested on day 0 (72 hours post final HDM 
exposure), 48 and 96 hours after bacterial infection. (A) Airway and (C) lung total viable cell 
numbers. Data presented as box and whisker with the median of 5 per group representative 
of 3 independent experiments’ *P<0.05; ** P<0.01. (B) Airway and (D) lung cell counts 
presented as percentage of baseline (0 hour after infection).  
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Figure 3.5: Airway and lung eosinophils and CD4 T cells of HDM- exposed and control 
mice after Streptococcus pneumoniae (S.pn) challenge. BALB/c mice were inoculated 
intranasal with 15µg of house dust mite (HDM) extract in 15µl phosphate-buffered saline 
(PBS) or 15µl PBS alone three times a week for 3 weeks and subsequently infected with 
1x106 CFU of Streptococcus pneumoniae (D39 strain). Samples were harvested on day 0 
(72 hours post final HDM exposure), 48 and 96 hours after bacterial infection. The numbers 
of (A, B) CD11b+SiglecF+ eosinophils and (C, D) CD3+CD4+ T cells in the allergic airways 
and lungs were determined by flow cytometry. Data presented as box and whisker with the 
median of 5 per group representative of 3 independent experiments. *P<0.05; ** P<0.01. 
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3.2.4 HDM exposure reduces recruitment of neutrophils to the airways and 
lung 
Neutrophils are an important cell type in anti-bacterial immunity. Next, it was 
examined whether their recruitment was affected by prior HDM exposure. Neutrophil 
numbers were significantly higher in the lungs of HDM (p=0.0317) exposed mice 
prior to bacterial infection unlike the airways (0h) (Fig. 3.6A & B). This lung 
neutrophil infiltrate to HDM has been described before120. There was a substantial 
increase in neutrophils in PBS treated mice in response to S. pneumonia at 48 
hours. However, this increase was blunted in HDM exposed mice in both airways 
and lung (Fig. 3.6). On comparison to PBS, neutrophil numbers in the allergic group 
were significantly reduced 48 hours after infection in BAL (p=0.0079) and lung. At 96 
hours post infection there is no difference in neutrophil numbers between the two 
groups and they had essentially returned to pre-infection levels.  
The impairment of neutrophil recruitment in HDM exposed mice may be a result of 
structural changes in the lung or reduced chemotactic signals (Fig. 3.7A). Therefore, 
after 3 weeks of HDM or PBS exposure, mice were given recombinant CXCL1 (1µg 
CXCL1/mouse), which is an important mouse neutrophil chemoattractant. HDM 
exposed mice (without infection) were able to recruit as many neutrophils as PBS 
controls after CXCL1 exposure (Fig. 3.7B) into the airways and lung (Fig. 3.7C). 
This suggests that chemotactic signals for neutrophils may be reduced in the 
asthmatic lung and that perhaps their restoration could prevent subsequent bacterial 
infection. 
 
3.2.5 Instillation of CXCL1 or CXCL2 to the HDM-exposed lung restores anti-
bacterial immunity 
The HDM-exposed lung is clearly deficient in multiple factors required for clearance 
of S. pneumoniae and this deficit likely occurs at the level of innate recognition and 
responsiveness of TLRs. We therefore attempted to bypass this deficiency by 
restoring the neutrophil chemoattractants, CXCL1 or CXCL2 (Fig. 3.7D). Intranasal 
administration of CXCL1 or CXCL2 at the time of infection (72 hours following 
cessation of HDM) restored Ly6G+ neutrophil numbers in the airway and lung and  
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Figure 3.6: Reduced neutrophil numbers in HDM- exposed mice following bacterial 
challenge. (A) Airway and (B) lung neutrophil (identified by flow cytometry as CD11b+ 
Ly6G+) recruitment in HDM- or PBS- exposed group were compared after intranasal 
administration of Streptococcus pneumoniae (S.pn). Data presented as box and whisker 
plots with the median. *P<0.05; ** P<0.01. Data show representative samples of five per 
group from one experiment and are representative of three independent experiments. 
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Figure 3.7: Equivalent numbers of neutrophils are recruited into the airways and lungs 
of control (PBS) and HDM- exposed mice after recombinant CXCL1 or CXCL2 
instillation. (A) An illustration of the CXCL1 administration protocol. (B) Airway and (C) lung 
neutrophil (identified as CD11b+Ly6G+ by flow cytometry) recruitment in HDM- or PBS- 
exposed mice was analysed 6 and 24 hours after intranasal administration of 1µg of 
recombinant murine CXCL1 per mouse on day 0. (D) An illustration of CXCL1 or CXCL2 with 
or without S. pneumonia administration protocol. Airway and lung bacterial titres were 
determined 6 hours after infection +/- (E) CXCL1 or (F) CXCL2. Administration of 1µg 
recombinant murine (G) CXCL1 or (H) CXCL2 per mouse overcomes the inability of HDM 
exposed group to recruit neutrophils 6 hours after bacterial infection. Box and whisker plots 
of 5 per group representative of 2 experiments. *P<0.05; ** P<0.01.  
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the neutrophil numbers even exceeded those in the PBS control group 6 hours after 
infection (Fig. 3.7G & H). Bacterial CFU in the airway and lung were significantly 
reduced in HDM-sensitised group where CXCL1 (Fig. 3.7E) or CXCL2 (Fig. 3.7F) 
had been restored. Furthermore, there was a significant reduction in the percentage 
of neutrophils in the blood after i.n CXCL2 administration suggesting an improved 
migration of neutrophils from blood to the airways and lungs (Fig. 3.8A), whereas 
there was no change in the percentage of neutrophils in the bone marrow between 
the groups that received CXCL2 and those that did not (Fig. 3.8B). 
 
3.2.6 Reduced anti-bacterial cytokine production in the allergic airways  
To evaluate further the cause of the impaired neutrophil recruitment, cytokines and 
chemokines essential for neutrophil recruitment to sites of infection were assessed. 
The trend for all cytokines and chemokines (TNF, IL-6, CXCL1 and CXCL2) 
measured was a significant reduction in HDM exposed mice compared to PBS 
controls at early hours after infection (6 hours) (Fig. 3.9A-E). Both CXCL1 and 
CXCL2 act on the chemokine receptor CXCR2 on neutrophils. TNF levels were 
significantly reduced at 4 (p=0.0225) and 48 hours (p=<0.0001) after S. pneumonia 
infection compared to PBS (Fig. 3.9A). MMP-9 airway levels were studied as it 
cleaves CXCL1 into a 10-fold more potent form235. 
CXCL1 is an important neutrophil chemoattractant secreted mainly by epithelial and 
macrophages in response to infection. Therefore, we next sought to identify CXCL1 
production by airway epithelial cells. Immunohistochemistry of lung sections showed 
that CXCL1 was strongly expressed in PBS, while levels comparable to control (no 
primary antibody added) were visible in HDM exposed mouse lung sections, 4 hours 
after infection (Fig. 3.9F).  
IL-17A is an important stimulus for granulocyte-colony stimulating factor (G-CSF) 
secretion that is essential for production of neutrophils. Furthermore, endothelial 
cells activated by IL-17A can release CXCL1 and CXCL2 that activate and recruit 
neutrophils. Major IL-17A producing cells are γδ T cells, CD4+ Th17 and natural killer 
T (NKT) cells236. Therefore, the number of IL-17 producing cells in the lungs were 
examined. There were significantly (p=0.0079) elevated numbers of Th17 cells 72  
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Figure 3.8: CXCL2 administration to HDM- exposed group reduces blood neutrophil 
levels. The frequency of (A) blood and (B) bone marrow neutrophils were determined by 
flow cytometry. Data presented as box and whisker plots showing the median of n=5 per 
group in 2 independent experiments.  *P<0.05; ** P<0.01. 
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Figure 3.9: Airway cytokine and chemokines levels after Streptococcus pneumoniae 
infection. Quantification of (A) TNF, (B) IL-6, (B) CXCL1 (D) CXCL2 and (E) MMP-9 in the 
bronchoalveolar lavage (BAL) fluid by ELISA. Data presented are the means ± SD *P<0.05; 
** P<0.01; *** P<0.001. (F) Immunohistology of formalin fixed lung tissue for CXCL1. Brown 
coloured stain shows CXCL1 on the lung sections detected by HRP-DAB and examined by 
light microscopy (original magnification x 40) and is representative of the lungs from 5 mice 
per group. 
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hours after the final HDM exposure compared to PBS controls that wanes down to 
PBS levels 120 hours after the final exposure (Fig. 3.10A). However, after S. 
pneumoniae infection there was no difference in Th17 cells in the lungs between the 
two groups. IL-17 producing γδ T cells were similarly high in HDM exposed mice 
(72h after final exposure) and reduced to PBS levels by 120 hours in the absence of 
infection or allergen (Fig. 3.10B). Similar to Th17 cells, there was no difference in IL-
17+ γδ T cells 48 hours after infection. This suggests that impairment in IL-17 
production from CD4+ T cells or γδ T cells is not responsible for the impaired 
neutrophil recruitment and subsequent bacterial complications in HDM exposed 
group. There was no difference in total IL-17 secretion examined by ELISA between 
PBS and HDM exposed mice (Fig. 3.11).  
 
3.2.7 Reduced pro-inflammatory receptor expression on key anti-bacterial 
immune cells 
The expression of TLRs on key innate immune cells such as macrophages (airway 
CD11c+TLR2+) and neutrophils (airway CD11b+Ly6G+TLR2+) were investigated. In 
particular, we analysed TLR2, as it is an important PRR in gram-positive bacterial 
infections. HDM exposure significantly reduced TLR2 expression measured as 
frequency of CD11c+ macrophages and CD11b+Ly6G+ neutrophils in the airways 
when analysed 72 hours after final HDM exposure (Fig. 3.12A-F). Even following S. 
pneumoniae infection (48 hours), HDM exposure significantly reduced TLR2 
expression compared to PBS controls. The percentage of airway neutrophils 
(p=0.0079) and alveolar macrophages (p=0.0317) expressing TLR2 were also 
significantly reduced in the HDM exposed group compared to PBS controls 48 hours 
after infection. However, at 96 hours, TLR2 expression was similar between the PBS 
and HDM groups and had returned to levels prior to infection (Fig. 3.12A & B).  
Another important innate immune receptor on neutrophils is TREM1 that modulates 
the innate response by amplifying TLR-induced cytokine secretion for better anti-
microbial immunity215. HDM exposed group had a significantly reduced percentage 
(Fig. 3.12G) and total number (Fig. 3.12H) of TREM1+ neutrophils in the airways at 
78 (p=0.0079) and 96 (p=0.0159) hours after the final HDM challenge. 
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Figure 3.10: Elevated IL-17A producing CD4+ and γδ TCR expressing T cells in the 
HDM- exposed airways compared to PBS controls. 48 hours after Streptococcus 
pneumonia infection the number of IL-17A producing (A) CD4+  and (B) γδ TCR expressing 
T cells were determined in lung by flow cytometry. n=5 per group.  *P<0.05; ** P<0.01. 
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Figure 3.11: IL-17A levels in the airways of HDM- exposed airways compared to PBS 
controls. HDM-exposed and PBS control mice were infected with S. pneumoniae and at the 
time points shown BAL performed. IL-17A (pg/ml) levels in BAL supernatant were measured 
by ELISA after S. pneumonia infection.  
 
pg/ml	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Figure 3.12: Reduced expression of pathogen recognition receptors (PRRs) on 
macrophages and neutrophils in allergic mice compared to PBS controls. BALB/c mice 
were inoculated intranasal with 15µg of house dust mite (HDM) extract in 15µl phosphate-
buffered saline (PBS) or 15µl PBS alone three times a week for 3 weeks and harvested on 
72 hours post final HDM exposure. Expression of surface TLR2 involved in bacterial 
recognition on (A, B) airway neutrophils and (C, D) CD11c+ airway macrophages is shown 
as percentage of cells and representative histograms and was determined by flow cytometry.  
Total cell counts of TLR2 positive (E) neutrophils and (F) CD11c+ macrophages in the 
airways were calculated from total viable cells. (G) Percentage of total airway cells that are 
Ly6G+TREM1+ and (H) total cells number of Ly6G+TREM1+ airway cells. Data presented 
as box and whisker plots with the median of n = 5 in 2 independent experiments. *P<0.05; ** 
P<0.01. 
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Dead cells were excluded using a live/dead marker. In contrast, TREM2, mainly 
expressed on macrophages, inhibits TLR-induced cytokine production. The 
percentage of airway macrophages identified as CD11c+ cells that expressed 
TREM2 was significantly higher in HDM exposed airways than PBS controls 
measured three days after the final HDM exposure (p=0.0079) (Fig. 3.13A & B).  
Inhibition of TLR responsiveness can also occur by the up-regulation of receptors 
that recruit similar adapter molecules to initiate signalling.  In this respect it is 
interesting that the IL-33 receptor, ST2L (associated with development of allergic 
airway disease) that recruits the TLR signalling adapter myeloid differentiation factor 
88 (MyD88) 93 is raised on CD11c+ airway macrophages (Fig. 3.13C) together with 
the negative regulator CD200R (Fig. 3.13D) in the HDM-sensitised lung at the onset 
of bacterial infection. 
Additionally, analysis of intracellular TLR negative regulators (A20, Tollip, IRAK-M 
and Triad3A) by real time PCR revealed a trend of increased mRNA transcripts of 
these inhibitors in HDM exposed lungs compared to PBS controls (Fig. 3.14). 
Therefore, the TLR responsiveness of airway macrophages and neutrophils is 
inhibited on many levels.  
Furthermore, anti-microbial peptides were comparable in airway lavage of PBS and 
HDM exposed mice. A recently identified antimicrobial protein SPLUNC1 produced 
by epithelial cells has an important role in M. pneumoniae clearance, but is reduced 
in mouse models of allergic inflammation166,237. However, reduced levels of 
SPLUNC1 were not detected in the HDM exposed airway fluid (in fact there seems 
to be more in HDM airway fluid, Fig. 3.15A) and only a partial decrease in CRP that 
opsonses S. pneumoniae for opsonophagocytosis in HDM-sensitised mice (Fig. 
3.15B). 
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Figure 3.13: Increased expression of regulatory receptors on macrophages (CD11c+ 
cells) in allergic mice compared to PBS controls.  BALB/c mice were inoculated 
intranasal with 15µg of house dust mite (HDM) extract in 15µl phosphate-buffered saline 
(PBS) or 15µl PBS alone three times a week for 3 weeks and harvested on 72 hours post 
final HDM exposure. (A) Percentage and (B) total cell count of TREM2 positive alveolar 
macrophages (CD11c+) 78 hours after final HDM exposure. Percent of CD11c+ 
macrophages expressing (C) ST2L or (D) CD200R was determined by flow cytometry. Data 
presented as box and whisker plots with the median of n=5 in 2 independent experiments. 
*P<0.05, ** P<0.01. 
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Figure 3.14: Expression of TLR negative regulators in whole lung of allergic mice were 
compared to PBS controls. BALB/c mice were inoculated intranasal with 15µg of house 
dust mite (HDM) extract in 15µl phosphate-buffered saline (PBS) or 15µl PBS alone three 
times a week for 3 weeks and harvested on 72 hours post final HDM exposure. The level of 
different RNA transcripts, as indicated, was assessed at this time point by real-time PCR. 
Results are expressed as the ratio between the gene of interest and a PBS control sample.  
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Figure 3.15: Antimicrobial substances in HDM- sensitised group after bacterial 
infection. HDM-exposed and control mice were infected with S. pneumonia and (A) short 
palate, lung and nasal epithelium clone 1 (SPLUNC1) 6 hours after infection detected by 
western blotting. Data representative of 2 independent experiments of n=2-3 per group. (B) 
C-reactive protein (CRP) levels were measured by ELISA. Data is presented as box and 
whisker plots showing the median of n=5 per group in 2 independent experiments.  *P<0.05.  
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3.2.8 Exacerbation of bacterial infection wanes without re-exposure to allergen 
In order to determine whether the timing of bacterial exposure is critical, HDM was 
given on alternate days for 3 weeks and 3, 7, 10 or 14 days after the last HDM 
exposure infected with S. pneumoniae (Fig. 3.16A). Invasion of lung tissue with 
bacteria was lost after an absence of HDM for 7 days. The proportion of lungs 
harbouring bacteria at 48 hours after S. pneumoniae infection also reduced after day 
3 of an absence of allergen, but never reached the low level shown in PBS exposed 
mice (Fig. 3.16B). The improvement with increasing time post allergen exposure 
was associated with a return in the ability to recruit neutrophils to the airspaces (Fig. 
3.16C) and a decrease in eosinophils (Fig. 3.16D). This suggests that allergen 
exposure causes increased susceptibility to invasive bacterial infection within a 
specific time window but that some remain susceptible for prolonged periods of time, 
and that allergen load may be a factor in determining the seriousness of concomitant 
bacterial infection. 
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Figure 3.16: The percentage of lungs with bacteria reduces and the numbers of 
neutrophils in the airways of HDM/Streptococcus pneumoniae challenged group 
increases as HDM exposure wanes. (A) Experimental design: Five BALB/c mice per group 
were inoculated intranasal with 15µg of house dust mite (HDM) three times a week for 3 
weeks and subsequently infected on days 3, 7, 10 and 14 after final house dust mite (HDM) 
administration and harvested 48 hours after infection. (B) The percentage of with bacteria 
reduces as HDM exposure wanes. (C) The frequency of CD11b+Ly6G+ neutrophils and (D) 
CD11b+SiglecF+ in the airways were determined by flow cytometry. The dotted line illustrates 
PBS/S. pneumonia infected group harvested 48 hours after infection (baseline). Data 
presented as box and whisker plots with the median of n=5 per group in two independent 
experiments.  *P<0.05. 
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3.3 Discussion  
In this chapter we focused on susceptibility of the allergic lung to S. pneumonia 
infection. We show for the first time that HDM exposed mice have increased 
susceptibility to S. pneumonia, that the molecular pathways leading to the production 
of neutrophil chemoattractants in the lung are compromised and that despite the 
complexity of anti-bacterial pathways that are disrupted, the re-introduction of 
neutrophils by i.n administration of neutrophil chemoattractants to lungs with allergic 
airway disease enables clearance of S. pneumoniae that would otherwise prove 
fatal. 
 
3.3.1 Allergen exposure increases susceptibility to respiratory bacterial 
infections 
In our study the effect of HDM exposure prior to bacterial infection was analysed. 
Intranasal inoculation of HDM exposed mice with S. pneumonia resulted in 
significantly increased bacterial titres in BAL and lung compared to PBS exposed 
controls, suggesting increased replication of S. pneumonia or a reduced clearance of 
the bacteria from the allergic lung. Furthermore, the severity of disease was so high 
in the HDM exposed mice that some mice were sacrificed 3 days after infection.  
Neutrophils are essential to eliminate S. pneumonia. However, the findings in this 
chapter show that HDM exposed lungs are unable to recruit as many neutrophils as 
the PBS controls after bacterial infection. Rolling and attachment of neutrophils to 
sites of infection is determined by adhesion molecule (selectins and integrins) 
expression on endothelial cells that increases in response to TNF-α, IL-1β and IL-
17238. The effect of TNF-α is essential during early stages of infection in recruiting 
neutrophils and enhancing anti-bacterial cytokine secretion. A number of studies 
have shown blocking/neutralising TNF-α to be detrimental in S. pneumonia infection 
137,139,239-241. Analysis of most of these chemokines and cytokines in the airways 
revealed significantly reduced levels after bacterial infection in HDM exposed 
compared to controls. Therefore, the signals needed to attract neutrophils are 
impaired in allergic airways. To support this Zhao et al show reduced production of 
IL-17 in OVA sensitised/challenged lungs compared to controls after S. pneumoniae 
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serotype-3 infection242. When the impaired chemotactic signal was restored by 
administering intranasal CXCL1 or CXCL2, the impaired neutrophil recruitment 
diminished and the bacterial clearance improved considerably. 
Most MMPs degrade proteins of the extracellular matrix (ECM). However, MMP-9 
can also break down a variety of non-ECM proteins such as chemokines and myelin 
basic protein243. Furthermore, MMP-9 cleaves IL-8 into a form that is 10-fold more 
potent243 244 and activates TNFα. Therefore the reduced neutrophil recruitment may 
not only be due to reduced CXCL1, but also a reduction in this more active form due 
to alterations in MMP-9 activity. MMP-9 deficiency reduces systemic bacterial 
clearance245. The role of MMP-9 in asthma is controversial with airway and sputum 
levels noted as elevated in asthmatic patients246 that is mimicked in vivo models 
where MMP-9 inhibition caused reduced airway hyperresponsiveness247. However, 
MMP-9-/- show enhanced allergen-induced airway inflammation248. Moreover, the 
role of MMP-9 has not been studied in HDM model of allergic airway disease. 
Therefore, the proteolytic cleavage of CXCL1 (murine homologue of human IL-8) to 
a more biologically active one may be defective in the HDM exposed lung as a result 
of reduced MMP-9 (and/or other chemokine endopeptidases).  
The airway epithelium and alveolar macrophages are the first line of host defense 
against environmental antigens. Airway epithelial cells recognise invading microbes 
such as S. pneumonia and subsequently produce a range of mediators such as 
mucins to trap the pathogens for mucociliary clearance, cytokines and antimicrobial 
peptides (β-defensins and cathelicidin) and proteins (lactoferrin). A recently identified 
antimicrobial protein SPLUNC1 produced by epithelial cells has an important role in 
M. pneumoniae clearance, but is reduced in mouse models of allergic 
inflammation166,237. However, there was no reduction in anti-microbial peptide 
(SPLUNC1) in airway lavage and only a partial decrease in CRP in HDM-sensitised 
mice. In future experiments, CRAMP and defensins should be analysed in the airway 
fluid after HDM exposure with or without bacterial infection. We identify that airway 
macrophages seem to have a suppressed phenotype with increased expression of 
regulatory receptors such as the myeloid negative regulator CD200R and ST2L (IL33 
receptor) that inhibits the MAL component of the TLR signalling pathway (further 
analysed in Chapters 4 and 5).  
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3.3.2 Reduced PRR expression on innate immune cells  
PRRs provide early recognition and initiate the inflammatory response to infection. 
Several TLRs are implicated in the host response to S. pneumonia but, most 
importantly, TLR2 that recognises LTA on gram-positive bacteria amongst others. In 
models of pneumococcal meningitis, TLR2-/- show increased disease severity and 
higher bacterial titres compared to wild-type controls249,250. Similarly, in a 
nasopharyngeal carriage model, TLR2-/- show impaired clearance of bacteria145. 
Pneumococcal pneumolysin is detected by TLR4251,252. Overall, TLR4 may play a 
limited role in defense against S. pneumoniae as some studies show no difference 
between WT and TLR4-/- 145,253,254. MyD88 is an important signalling adaptor protein 
during TLR signalling and MyD88 deficiency increase susceptibility to S. 
pneumonia255,256. Heightened susceptibility of aged mice (19-20 months) compared 
to young mice (4-5 months) is attributed to reduced TLR 1, 2 and 4 protein levels in 
the lungs together with reduced NF–κB activation and reduced pro-inflammatory 
cytokines, TNF-α and IL-6, production257. Furthermore, IL-6 production is 
predominately dependent on TLR2258. Alveolar macrophages have a significant 
reduction in TLR2 expression in HDM exposed mice compared to controls, as well 
as an increased gene expression of TLR negative regulators- Tollip, A20, IRAKM 
and TRIAD3A (an E3 ubiquitin-protein ligase that enhances ubiquitination and 
proteolytic degradation of some TLRs though it has not been shown to act on 
TLR2259), in whole lung homogenate (Fig. 3.17). Collectively, TLR signalling 
cascades in the allergic lung are impaired in response to infection compared to non-
allergic lungs. 
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Figure 3.17: TLR2 signalling pathway leading to activation of NF-κB associated cytokine 
genes. TLR negative regulators (A20, Tollip, IRAK-M and A20) can inhibit this pathway at 
multiple sites.  
 
Not only was TLR2 downregulated but also TREM-1 (Triggering receptor expressed 
on myeloid cells-1) that is considered to be a potent amplifier of the inflammatory 
response to invading microbes. TREM-1 has a vital role in accelerating the induction 
of the early immune response to S. pneumoniae resulting in augmented bacterial 
clearance and improved survival260.   
To control excessive inflammation our immune system as a number of receptors that 
act as ‘off’ switches such as TREM2 expressed on macrophages, which we show is 
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increased. In vitro studies show increased TLR responsiveness and cytokine 
production in TREM2-/- or bone marrow derived macrophages silenced for TREM2 
using short hairpin RNAi261. Therefore, TREM1 is a positive regulator of cytokine 
synthesis and TLR activation, while TREM2 is a negative regulator. The allergic lung 
may cause TLR desensitisation as it has high levels of IL-4 that increases TREM2 
expression on airway macrophages187.  
Our results show that the allergen-exposed lung is defective in its ability to respond 
to bacteria (Fig. 3.18). This culminates in an inability to recruit neutrophils and 
ultimately results in bacterial invasion and bacteraemia. Furthermore, the 
reprogramming of the lung innate immunity after allergen exposure persists for 
prolonged periods of time.  
 
Figure 3.18: The attenuated innate immune response to infection in allergic-HDM exposed 
lungs explored in this chapter. In our studies so far we have shown that HDM exposed lungs 
produce reduced levels of neutrophil chemoattractants such as KC/CXCL1, IL-6 and TNF 
(mainly produced by alveolar macrophages and airway epithelial cells) to recruit neutrophils. 
Furthermore, there is reduced expression of pathogen recognition receptors on neutrophils 
and alveolar macrophages. Collectively, they reduce the threshold of pathogen detection in 
the airways and lungs. 
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CHAPTER 4 
Probing macrophage dysfunction in the 
allergic lung. 
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CHAPTER 4 
4.1 Introduction  
In the airways, epithelial cells together with alveolar macrophages are the first cells 
to interact with allergens and respiratory pathogens. Macrophages play a crucial role 
in innate and adaptive immunity in response to microorganisms and are major 
mediators of the inflammatory response. Alveolar macrophages maintain lung tissue 
homeostasis and scavenge pathogens and debris. The last chapter showed that 
bacterial infection was exacerbated in the allergic lung and further analysis implied a 
substantial affect of airway macrophages.  
 
4.1.1 Macrophages in allergic airways disease 
Allergic airways disease is more robust in the absence of alveolar macrophages- 
depletion of alveolar macrophages in OVA-sensitised lungs before OVA challenge 
results in increased AHR and pulmonary eosinophilia262 suggesting they play an anti-
allergic role in this specific model. Furthermore, allergen-sensitised alveolar 
macrophages show a reduced capacity for phagocytosis and, consequently, 
diminished production of anti-inflammatory mediators such as TGF-β and 
prostaglandin E2 (normally released when alveolar macrophages phagocytose 
apoptotic cells)263. 
In response to the microenvironment macrophages can assume a number of 
different phenotypes and roles. In a Th2 rich cytokine (IL-4 and IL-13) environment 
macrophages become alternatively activated, however, IL-4Rα-induced AAMs do not 
play a role in protection against allergic airway disease264. HDM challenge induces 
higher numbers of AAMs which correlates with higher eosinophil numbers265. In 
addition HDM exposure of the rat alveolar macrophage cell line (NR8383) liberates 
pro-inflammatory mediators such as nitric oxide266. This pro-inflammatory phenotype 
is also observed on Dermatophagoides farinae exposure that causes NF-κB 
activation in alveolar macrophages and upregulation of IL-6, TNFα and nitric 
oxide267. In a recent paper, resident alveolar macrophages are shown to gain pro-
inflammatory function after OVA sensitisation and challenge but have reduced 
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phagocytic capacity and increased production of cytokines and chemokines in 
response to TLR3 (poly I:C), TLR4 (LPS) and TLR7 (imiquimod) ligands268. This 
reduced phagocytic activity in inflammation is interesting since influenza infection 
also desensitises alveolar macrophages to TLR ligands53. This suggests that generic 
processes, rather than antigen specific influences may be responsible. Since 
bacterial phagocytosis, phagolysosomal destruction and/or recruit inflammatory cells 
to the site of infection using chemokines and acute phase proteins269 are critical for 
anti-bacterial immunity, subsequently alveolar macrophages were examined in more 
detail. 
 
4.1.2 Regulation of immune cells by Micro RNAs 
A number of studies show miRNAs can regulate TLR signalling270. miRNAs are short 
double-stranded RNA molecules approximately 22 nucleotides long and repress the 
translation of target mRNAs270,271. The RNA silencing depends on sequence specific 
interaction between the target RNA molecule and a small RNA incorporated into the 
RNA-induced silencing complex272. The binding of this complex inhibits the 
expression of mRNA either through degradation (removal of the polyA tail of target 
mRNA) or blockade of translation. Many miRNAs target cell-signalling pathways.  
 
4.1.3 Hypothesis and Aims 
Data presented in the earlier chapter show that neutrophil recruitment is defective in 
the airways of S. pneumonia infected allergic mice compared to non-allergic controls 
possibly due to reduced neutrophil recruiting cytokines and chemokines. As one of 
the first cells to contact airborne bacteria, alveolar macrophages are essential in 
initiating an effective anti-bacterial response including neutrophil recruitment. 
Therefore, the next aim was to determine the anti-bacterial capacity of resident 
alveolar macrophages in the HDM exposed airways. The specific aims are: 
1. To define the phenotype of resident alveolar macrophages.  
2. To examine the response of alveolar macrophages to bacterial components 
(TLR agonists). 
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4.2 Results 
4.2.1 Reduced airway neutrophil levels after TLR stimulation in vivo 
The ability of the allergic airway to support neutrophil migration in response to 
specific TLR stimulation was assessed. Administration of TLR2 (LTA), 4 (LPS) and 5 
(flagellin) ligands (Fig. 4.1A) induced significantly increased cellular infiltrate into the 
airways (Fig. 4.1B) and lung (Fig. 4.1C) of mice exposed to PBS and especially 
HDM. However, the percentage of infiltrating (CD11b+) cells that were Ly6G+ 
neutrophils was reduced in the airways and lung of allergen exposed mice compared 
with PBS controls (Fig. 4.1D & E). The ratio of neutrophils to eosinophils was similar 
after flagellin (Fig. 4.2B) challenge between the PBS and HDM exposed groups. 
However, after LPS and LTA (Fig. 4.2C & D) challenge, the ratio of neutrophils was 
considerably higher than eosinophils. Cytokine and chemokine levels in the 
airspaces of HDM-exposed mice were compared to PBS controls following TLR 
challenge. Cytokines, IL-6 and TNFα were not detectable at 16 hours after TLR 
agonist challenge (data not shown). The neutrophil chemoattractant CXCL2 was also 
undetectable at the time point tested (the chemokine levels may have been 
detectable at earlier timepoints after TLR stimulation); while, CXCL1 was detected 
mainly in the HDM exposed airways (Fig. 4.3). Within the PBS groups, CXCL1 was 
significantly elevated in response to LPS compared to no agonist PBS group. These 
data together with our previous work on reduced neutrophil recruitment following 
Streptococcus pneumoniae infection in the allergic airways show reduced response 
to bacterial pathogen recognition receptors.  
 
4.2.2 HDM exposure changes resident alveolar macrophage 
Alveolar macrophages can initiate the recruitment of neutrophils via secretion of 
relevant chemokines. Therefore, alveolar macrophages were examined in more 
detail. Alveolar macrophages express high levels of the integrin CD11c (that is not 
expressed by other macrophages)273 and low levels of CD11b. The longevity of 
alveolar macrophages was assessed by i.n. administration of a dye PKH26-PCL 
(Sigma) that is ingested by phagocytic cells in the airways (Fig. 4.4A). The dye was  
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Figure 4.1: Neutrophil recruitment in response to in vivo stimulation of TLR2, TLR4 
and TLR5 ligands. BALB/c mice were inoculated intranasal with 15µg of house dust mite 
(HDM) extract in 15µl phosphate-buffered saline (PBS) or 15µl PBS alone three times a 
week for 3 weeks and 72 hours post final HDM exposure 10µg LPS, 50µg LTA and 2µg 
Flagellin was administered. (A) Illustration of HDM and TLR agonist administration protocol. 
Total (B) airway and (C) lung cells were enumerated before and after TLR agonist addition. 
Percentage of Ly6G+ CD11b+ CD11c- neutrophils was assessed by flow cytometry in the 
(D) airway and (E) lungs. Data presented as box and whisker plots with the median of n=5 
per group in two independent experiments.  *P<0.05. 
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Figure 4.2: Proportion of neutrophils and eosinophils in response to in vivo 
stimulation of TLR2, TLR4 and TLR5 ligands. BALB/c mice were inoculated intranasal 
with 15µg of house dust mite (HDM) extract in 15µl phosphate-buffered saline (PBS) or 15µl 
PBS alone three times a week for 3 weeks and 72 hours post final HDM exposure 10µg 
LPS, 50µg LTA and 2µg Flagellin. (A-D) shows the proportion of neutrophils and eosinophils 
between PBS and HDM groups in the airways. Data presented as mean+SEM of n=5 per 
group.  *P<0.05.  
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Figure 4.3: CXCL1 levels in response to in vivo stimulation of TLR2, TLR4 and TLR5 
ligands in the airways. BALB/c mice were inoculated intranasal with 15µg of house dust 
mite (HDM) extract in 15µl phosphate-buffered saline (PBS) or 15µl PBS alone three times a 
week for 3 weeks and 72 hours post final HDM exposure 10µg LPS, 50µg LTA and 2µg 
Flagellin. CXCL1 levels in the airways. Data presented as box and whisker plots with the 
median of n=5 per group. Significance compared to PBS group with TLR agonist. *P<0.05, ** 
P<0.01. 
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Figure 4.4: In vivo labelling of resident alveolar macrophages. PKH26-PCL (Sigma) 
labels cells with phagocytic capabilities through ingestion of dye micro-aggregates. (A) We 
administered dye to BALB/c mice 72 hours before the first house dust mite (HDM) exposure 
and then exposed the mice to three weeks of 15µg HDM or 15µl PBS (3 times a week). (B) 
Flow cytometry plots show uptake of dye at the time of the first HDM exposure (72 hours 
after dye inoculation). (C) The gating strategy used to analyse PKH26-PCL dye+ airway cells 
and the majority of these cells are (D) F4/80+. Data presented as representative flow 
cytometry plots.  
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given 72 hours before the start of HDM exposure. PKH26-PCL administration 
allowed us to track the phenotype of this starting population following subsequent 
exposure to allergen (Fig. 4.4A). 75% of CD11c+ airway cells were dye+ at the start 
of HDM exposure (Fig. 4.4B).  A comparable percentage of dye+ macrophages were 
evident following three weeks of HDM exposure (Fig. 4.4C) that were also F4/80+ 
(Fig. 4.4D). The majority of dye+ CD11c+ cells (98%) were CD11b- (Fig. 4.5A). 
About 20% of airway CD11c+ macrophages did not take up dye at the start of the 
experiment and a comparable percentage was present after three weeks of HDM 
exposure. These dye-CD11c+ airway cells showed a similar phenotype as the dye+ 
cells (upregulated regulatory receptors and alternatively activated markers). This 
data suggests that airway macrophages are long lived and are either non-migratory 
or return to the airspaces rapidly. Therefore, macrophages that ingested the PKH26-
PCL dye before the start of HDM exposure (in a naïve airway) were the resident 
alveolar macrophages (PKH26-PCL dye+ and CD11c+). Both PBS and HDM 
exposed mice had comparable numbers of dye+ alveolar macrophages (Fig. 4.5B). 
Although, the percentage of airway myeloid cells that were CD11c+Dye+ reduced 
after HDM exposure as a result of increased cellular infiltrate following allergen 
exposure. HDM exposure increased the percentage (Fig. 4.6 left), geomean (Fig. 
4.6 middle) and total numbers (Fig. 4.6 right) of ST2L (IL-33R or T1/ST2) and 
Triggering Receptor Expressed on Myeloid Cells (TREM2) on dye positive 
macrophages that are associated with decreased TLR responses. Therefore, an 
increase in these regulatory receptors indicates an altered phenotype of 
macrophages after HDM exposure. Messenger RNA analysis of the sorted 
dye+CD11c+ alveolar macrophage after 3 weeks of HDM exposure also highlighted 
increased levels of arginase I, resistin-like molecule alpha (RELMα) and YM1, 
expression of which are characteristic of AAM phenotype (Fig. 4.7A). In addition, 
RELMα and YM1 proteins were only present in the allergic lung when assessed by 
immunohistochemistry (Fig. 4.7B). Thus, alveolar macrophages in the HDM-
exposed lung are altered in phenotype towards an alternatively activated or wound 
healing phenotype. 
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Figure 4.5: Total dye positive resident alveolar macrophages. PKH26-PCL (Sigma) dye 
micro-aggregates were intranasal inoculated to BALB/c mice 72 hours before the first house 
dust mite (HDM) exposure and then mice were exposed to three weeks of 15µg HDM or 
15µl PBS (3 times a week). (A) Flow cytometry plot to show dye+CD11c+ airway 
macrophages are CD11b-. (B) Percentage of dye+ airway myeloid cells and total airway 
cells was determined by flow cytometry. Data presented as box and whisker plots with the 
median of n=5 per group in two independent experiments.  *P<0.05. 
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Figure 4.6: Regulatory receptors T1/ST2 and TREM2 expression on CD11c+Dye+ and 
CD11c+Dye- airway cells. PKH26-PCL (Sigma) dye was given (intranasal) to BALB/c mice 
72 hours before the first house dust mite (HDM) exposure and then exposed mice to three 
weeks of 15µg HDM or 15µl PBS (3 times a week). Flow cytometry was used to analyse 
T1/ST2 and TREM2 expression on dye positive and negative alveolar macrophages. Data 
presented as box and whisker plots with the median of n=5 per group in two independent 
experiments.  *P<0.05.  
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Figure 4.7: Analysis of alternatively activated markers RELMα, YM1 and Arg1 in 
CD11c+dye+ airway cells. PKH26-PCL (Sigma) dye that stains only phagocytic cells was 
intranasal inoculated to BALB/c mice 72 hours before the first house dust mite (HDM) 
exposure and mice then exposed to three weeks of 15µg HDM or 15µl PBS (3 times a 
week). The alternatively activated markers were measured by (A) real-time PCR and (B) 
immunohistochemistry. Data presented as box and whisker plots with the median of n=5 per 
group in two independent experiments.  *P<0.05, ** P<0.01. 
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4.2.3 Restoration of naïve alveolar macrophages restores anti-bacterial 
immunity in the allergic airway 
The next step was to assess whether administering naïve alveolar macrophages to 
the allergic lung would restore the anti-bacterial immune response. Alveolar 
macrophages express high levels of CD11c and low expression of CD11b compared 
to other lung macrophages273. 1x105 CD11c+CD11b- alveolar macrophages from 
naïve or HDM exposed lungs were purified by flow sorting and transferred intranasal 
to allergic mice 48h after the final HDM exposure and 18h before Streptococcus 
pneumonia infection (Fig. 4.8A). The allergic lungs that received alveolar 
macrophage from age matched naïve mice performed better in removing bacteria 
from the airways and lung compared to allergic lungs that received HDM-exposed 
allergic alveolar macrophages or allergic lungs without cell transfer (Fig. 4.8B-C). 
Furthermore, allergic mice receiving naïve alveolar macrophages had more airway 
neutrophils (Fig. 4.8D & E) following S. pneumoniae challenge. A similar trend was 
seen when neutrophil recruitment was assessed 6 hours after infection, although the 
bacterial titres at this time point was not significantly different between the groups.   
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Figure 4.8: Transfer of naïve CD11c+CD11b- alveolar macrophages restores bacterial 
clearance in HDM exposed mice. (A) BALB/c mice were exposed to 15µg of HDM three 
times a week for three weeks. 48 hours after the final HDM exposure, allergen exposed mice 
were given intranasal 1x10^5 FACS sorted CD11c+CD11b- airway macrophages either from 
naïve or allergen exposed lungs. 18 hours after the cell transfer mice were infected with 
1x10^6 CFUs of Streptococcus pneumoniae strain D39 (B) Bacterial titres in the airways, 
lung and blood of the infected groups were determined by plating out respective issues. (C) 
Percentage of mice with bacteria in the different organs. Airway neutrophils (CD11c-
CD11b+Ly6G+SiglecF-) as (D) percentage of live airway cells and (E) total airway cell 
numbers. Figure includes data from two independent experiments. 
Chapter	  4:	  Probing	  macrophage	  dysfunction	  in	  the	  allergic	  lung.	  
	  
	  
118	  
4.2.4 Responsiveness of alveolar macrophages to TLR agonists ex vivo  
The next aim was to examine whether the reduced responsiveness of airway 
macrophages persisted ex vivo. Isolation of HDM exposed CD11c+CD11b- airway 
macrophages stimulated with LTA or LPS in vitro released significantly less TNF-α 
compared to controls (Fig. 4.9A). In addition, isolation of live dye+CD11c+ alveolar 
macrophages after three weeks of HDM exposure and ex vivo incubation with a 
range of TLR agonists, showed a similar reduction in TNFα to CD11c+DC11b- (Fig. 
4.9B), most significantly in response to flagellin (TLR5) and LPS (TLR4) stimulation. 
Similarly, lower levels of neutrophil chemoattractant protein, CXCL2 were released 
(Fig. 4.9C). CXCL1 was only decreased in response to bacterial flagellin (TLR5) 
(Fig. 4.9D). 
We next assessed in vitro whether it was the HDM or the cytokine milieu in the 
airway lavage that causes the changes in airway macrophages. To test this 0.5x10^6 
naïve airway cells (>90% are alveolar macrophages) were exposed to 200µl of 
5µg/ml HDM, 100µl media + 100µl BAL fluid from lungs exposed to PBS for 3 weeks, 
100µl media + 100µl BAL fluid from lungs exposed to HDM for 3 weeks or media 
alone overnight. Responses to TLR agonists 1µg/ml LTA (TLR2), 1µg/ml flagellin 
(TLR5) or 0.1µg/ml LPS (TLR4) were then assessed.  
Incubating naïve alveolar macrophages with HDM in vitro increased the production 
of TNFα after TLR 2, 4 and 5 stimulation compared to no HDM addition (Fig. 4.10). 
However, addition of BAL fluid from lungs exposed to PBS or HDM for 3 weeks, 
inhibited TNFα production (Fig. 4.10). This could be a result of the airways washed 
in HBSS with EDTA. As Hanks’ Salts are mainly used in media exposed to 
atmospheric condition as opposed to C02 incubation, incubating cells media with 
HBSS may exceed Hanks’ Salts in the buffer in a C02 environment and may result in 
cell death. To avoid these issues the experiment was repeated with the airways 
washed with PBS with no HBSS and EDTA (EDTA can detach adherent cells). Data 
from this experiment shows no difference in TNF response between cells exposed to 
airway fluid from PBS or HDM exposed mice after LPS or LTA stimulation (Fig. 
4.11).  
 
Chapter	  4:	  Probing	  macrophage	  dysfunction	  in	  the	  allergic	  lung.	  
	  
	  
119	  
 
Figure 4.9: TLR stimulation of sorted dye+ airway cells ex vivo. PKH26-PCL (Sigma) 
dye that stains only phagocytic cells was given (intranasal) to BALB/c mice 72 hours before 
the first house dust mite (HDM) exposure and then exposed the lungs to three weeks of 
15µg HDM or 15µl PBS (3 times a week). (A) FACS sorted 0.42x10^5 CD11c+CD11b- cells 
were stimulated with 1µg/ml LTA (TLR2) or LPS (TLR4) and TNFα was measured in the 
supernatant. (B) TNFα, (C) CXCL2 and (D) CXCL1 were measured in response to 0.3x10^5 
dye+ cells that were stimulated with 1µg/ml LPS (TLR4), LTA (TLR2), FLAG (flagellin, TLR5) 
or Pam3CSK4 (TLR1/2) agonists for 16-18 hours. White bars=PBS and Grey bars=HDM 
exposed alveolar macrophages in vivo. Data presented as mean+/-SD representative of two 
independent experiments.  *P<0.05, ** P<0.01.  
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Figure 4.10: TNF-α levels released by alveolar macrophages in vitro. Airways of naïve 
lungs were washed multiple times and red blood cell lysed. 0.5x10^6 cells were plated on a 
96-well plate. Cells were incubated for 2 hours in 5% CO2 at 37°C (for alveolar macrophages 
to stick to the plate). 2 hours later supernatants were removed and fresh media, 
media+5µg/ml house dust mite, media+bronchoalveolar lavage (BAL) washed in 
HBSS+EDTA from lungs exposed to PBS for 3 weeks or media+BAL from lungs exposed to 
HDM for 3 weeks were added to wells and incubated O/N. Subsequently, supernatants were 
removed and fresh media with or without TLR agonists (1µg/ml LTA (TLR2), 1µg/ml Flagellin 
(TLR5) or 0.1µg/ml LPS (TLR4)) were added and incubated for 4 hours. TNF-α was 
measured by ELISA. Data presented as mean with SD.   
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Figure 4.11: TNF-α production of naïve alveolar macrophages in response to TLR 
stimulation after HDM, IL-4 or IL-33 incubation. Airways of naïve lungs were washed 
multiple times and red blood cell lysed. 0.5x10^6 cells were plated on a 96-well plate. Cells 
were incubated for 2 hours (for alveolar macrophages to stick to the plate) in 5% CO2 at 
37°C. 2 hours later supernatants were removed and fresh media alone, 5µg/ml house dust 
mite, 20ng/ml recombinant IL-4, 20ng/ml recombinant IL-33, 100µl media+100µl 
bronchoalveolar lavage (BAL) washed in PBS from lungs exposed to PBS for 3 weeks or 
media+BAL from lungs exposed to HDM for 3 weeks were added to cells and incubated 
O/N. Subsequently, supernatants were removed and fresh media with or without TLR 
agonists: (A) 0.1µg/ml LPS (TLR4) or (B) 1µg/ml LTA (TLR2) were added and incubated for 
4 hours. TNF-α levels in the supernatant were measured by ELISA. Data presented as Mean 
with SD.  *P<0.05, ** P<0.01, *** P<0.001 using unpaired Student’s t test. All significances 
are to media only control (plus TLR stimulation). 
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Cytokines IL-4 and IL-33 are indicative of a Th2 response in the lungs120. Therefore, 
the next investigation was to examine whether addition of these cytokines to naïve 
alveolar macrophages induced changes that would result in lower production of 
TNFα to TLR stimulation. Overnight incubation of HDM or IL-4 induced significantly 
increased release of TNFα when TLR2 was stimulated by addition of LTA compared 
to media alone control or IL-33 incubation (Fig. 4.11B). No difference was seen 
between IL-33 and media alone control after LTA addition (Fig. 4.11B). Adding LPS 
(Fig. 4.11A) to cells incubated with IL-4 had considerably higher TNFα levels 
compared to media alone, HDM or IL-33 groups. IL-33 stimulated cells produced 
similar levels of TNFα as media alone control after both LPS and LTA. TNFα levels 
after overnight HDM and cytokine stimulation were undetectable without TLR 
stimulation. Therefore, the conclusion was that cytokines dominant in HDM-induced 
allergic airway disease do not individually account for the altered airway macrophage 
phenotype. 
 
4.2.5 Regulation of alveolar macrophages by regulators of TLR responses 
An increase in TLR negative regulator mRNA transcripts were observed in 
macrophages taken from the HDM exposed airways relative to PBS controls (tested 
in FACS sorted resident alveolar macrophages) comparable to increased TLR 
negative regulators seen in the whole lung after HDM exposure (chapter 3) (Fig. 
4.12). In particular, the TLR negative regulator A20 that targets TNF-receptor 
associated factor 6 (TRAF-6)274 was significantly increased in alveolar macrophages 
sorted by flow cytometry (Fig. 4.12A). TRAF-6 is an important intracellular 
component of TLR signalling pathway. A reduced response to TLR agonists was not 
explained by a reduction in mRNA transcript levels for TLR 2, 3 and 4 in HDM-
exposed alveolar macrophage; TLR9 was in fact significantly upregulated (Fig. 
4.12B).   
TRAF-6 and Interleukin-1 receptor associated kinase 1 (IRAK-1) are regulated by the 
microRNA, mmu-miR-146b-5p187 that was up-regulated in dye+ alveolar 
macrophages exposed to HDM compared to PBS when normalised to snoRNA 202 
and a PBS control sample (Fig. 4.13A). However, there was no difference in the  
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Figure 4.12: TLR and TLR negative regulators analysis of dye+ alveolar macrophages 
by real-time PCR. PKH26-PCL (Sigma) dye that stains only phagocytic cells was given 
(intranasal) to BALB/c mice 72 hours before the first house dust mite (HDM) exposure and 
then exposed the mice to three weeks of 15µg HDM or 15µl PBS (3 times a week). (A) TLR 
negative regulators Irak-M, A20, Tollip and Triad-3a and (B) TLR-2, 3, 4 and 9 mRNA levels 
are expressed relative to 18S and a PBS control sample. n=5 per group and 2 independent 
experiments performed. *P<0.05, ** P<0.01. 
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Figure 4.13: MicroRNA-146b and its targets TRAF-6 and IRAK-1. PKH26-PCL (Sigma) 
dye that stains only phagocytic cells was intranasal inoculated to BALB/c mice 72 hours 
before the first house dust mite (HDM) exposure and then exposed the lungs exposed to 
three weeks of 15µg HDM or 15µl PBS (3 times a week). (A) miR-146b levels are expressed 
relative to snoRNA 202 and a PBS control sample and were determined by RT-PCR. (B) 
mRNA for TRAF-6 and IRAK-1 are expressed relative to 18S and a PBS control sample. (C-
D) TRAF-6 and (E-F) IRAK protein expression was determined by flow cytometry in live 
CD11c+Dye+.   *P<0.05. 
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mRNA levels of IRAK-1 and TRAF-6 in dye+ airway macrophages (Fig. 4.13B). 
Consequently, intracellular protein expression of TRAF-6 and IRAK were determined 
by flow cytometry. The percentage of resident alveolar macrophages that express 
TRAF-6 (Fig. 4.13C-D) and IRAK (Fig. 4.13E-F) were significantly reduced in the 
airways of HDM exposed group compared to PBS controls. Therefore, the adaptor 
molecules of the TLR signalling pathway were altered by HDM exposure and the 
mRNA levels of their regulators are increased.  
 
4.2.6 Addition of macrophage chemoattractant protein, CCL2 restores anti-
bacterial immunity in the allergic airway 
Addition of alveolar macrophages benefited the allergic lung in clearing bacteria. 
Although, lungs that received naïve macrophages performed the best in bacterial 
elimination, in general addition of more macrophages reduced bacterial numbers in 
the airways and lung. A macrophage chemokine CCL2 (chemokine ligand-2) was 
next introduced in order to promote in vivo recruitment of macrophages and 
analysed bacterial response. 
Intranasal administration of 1µg of CCL2 in naïve mice resulted in an increase in 
airway cellular recruitment that peaked at 6 hours (Fig. 4.14A) but no significant 
change was observed in the lungs (Fig. 14B). Increase in airway cell recruitment 
correlated with an increase in airway myeloid cell numbers (Fig. 4.14C). At all 
timepoints tested the majority of the airway cells were CD11c+CD11b- (resident 
alveolar macrophages)  (Fig. 4.14D). Recruited macrophages numbers (CD11c-
CD11b+) (Fig. 4.14D) and neutrophils (Fig. 4.14E & F) also increased.  
In HDM-sensitised mice however, total airway and lung cell numbers reduced after 
addition of 1µg of CCL2 (Fig. 4.15A). This reduction was reflected in the reduced 
percent of live airway and lung myeloid cells that were CD11b+CD11c-, markers of 
recruited cells (Fig, 4.15 B & C) and eosinophils in the airways and lung (Fig, 4.15 D 
& E). 
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Figure 4.14: Airway cellular influx peaks 6 hours after administration of macrophage 
chemoattractant protein, CCL2. 1µg of CCL2 was intranasal inoculated per mouse and 0, 
2, 6 and 24 hours later analysis was performed. Total cell numbers in the (A) airways and 
(B) lungs. (C) Total numbers of live airway myeloid cells. (D) Percentage and numbers of 
resident alveolar macrophages (CD11c+CD11b-) and recruited airways cells (CD11c-
CD11b+). (E) CD11c+CD11c-Ly6G+ neutrophils as percentage of live myeloid airway cells 
and (F) total numbers in the airways by trypan blue exclusion. n=5 per group. 
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Figure 4.15: Addition of CCL2 reduces total cell numbers in the airways and lung of 
allergic mice. 1µg of CCL2 was i.n 48 hours after the final HDM exposure and lungs were 
analysed 24 hours later. (A) Total cell numbers in airways and lungs was enumerated by 
trypan blue exclusion. Percentages of live (dead cells excluded by fixable live/dead marker) 
myeloid cells that were CD11b+CD11c- (B) airway and (C) lung and the percentage of live 
myeloid cells that were eosinophils (D-E) was determined by flow cytometry. n=4 per group.  
*P<0.05. 
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The majority of cells in the airways of allergic mice were recruited CD11b+, whereas 
in PBS exposed airways the main cells were CD11c+ (Fig. 4.15B & 4.16B). Addition 
of CCL2 restored the dominance of CD11c+ macrophages in the airspaces of HDM 
exposed mice. More importantly CCL2 administration reduced the proportion of 
CD11c+ macrophages expressing ST2L (Fig. 4.16 C & D) and TREM2 (Fig. 4.16 E 
& F) that inhibit TLR responses and elevated the expression of TLR2 (Fig. 4.16G).  
Similarly, total numbers of CD11b+CD11c-, eosinophils, CD11c+ST2L+ and 
CD11c+TREM2+ were elevated in the allergic airways, but significantly reduced with 
CCL2 addition except CD11c+ST2L+ airway cells (Fig. 4.17A-D).      
When bacteria were introduced (Fig. 4.18A), the HDM exposed group that received 
CCL2 cleared bacteria better than the control HDM group (Fig. 4.18B). 33% of the 
mice in the HDM without CCL2 had bacteraemia, compared to none in the HDM with 
CCL2 group (Fig. 4.18C). There was no difference in airway or lung total cells 
numbers 48 hours after infection (Fig. 4.18D), though HDM+CCL2 mice had more 
cells than HDM group without CCL2 (Fig. 4.18E). 
As expected the majority (~80%) of airway myeloid cells after infection of PBS naïve 
mice were neutrophils; which dropped to ~30% in the HDM exposed airways (Fig. 
4.19A). However, CCL2 administration in HDM exposed airways improved neutrophil 
recruitment to over 40% (Fig. 4.19A). CCL2 i.n. before infection reduced the 
percentage of airway myeloid cells that were eosinophils (identified by FSC and SSC 
plots) (Fig. 4.19B). This environment created by CCL2 administration seemed to be 
better in neutrophil recruitment and bacterial clearance.  
Anti-microbial peptides that opsonise bacteria and enhance the uptake of bacteria by 
immune cells, were analysed after the introduction of new macrophages by either 
intranasal transfer or addition of CCL2. Although, the data showed no difference in 
SP-D and CRP levels with or without new macrophage recruitment in the airways 48 
hours after bacterial infection (Fig. 4.20).  
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Figure 4.16: Addition of CCL2 reduces anti-inflammatory receptors ST2L and TREM2 
on alveolar macrophages the airways. PKH26-PCL (Sigma) dye that stains only 
phagocytic cells was i.n to BALB/c mice 72 hours before the first house dust mite (HDM) 
exposure and then exposed the lungs to three weeks of 15µg HDM or 15µl PBS (3 times a 
week). 1µg of CCL2 was i.n 48 hours after final HDM exposure and 24 hours before 
infection. Percentages of live (dead cells excluded by fixable live/dead marker) airway 
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myeloid cells that were (A) CD11c+Dye+ or (B) CD11c+ was determined by flow cytometry. 
The percentage of (C) CD11c+Dye+ and (D) CD11c+ cells that are ST2L+ and the 
percentage of (E) CD11c+Dye+ and (F) CD11c+ cells that are TREM2+ airway. (G) 
Percentage of CD11c+ cells that are TLR2+. n=4 per group. *P<0.05. 
 
 
Figure 4.17: Addition of CCL2 reduces inflammatory airway cells. PKH26-PCL (Sigma) 
dye that stains only phagocytic cells was i.n to BALB/c mice 72 hours before the first house 
dust mite (HDM) exposure and then the mice exposed to three weeks of 15µg HDM or 15µl 
PBS (3 times a week). 1µg of CCL2 was i.n 48 hours after final HDM exposure and 24 hours 
before infection. Total airway (A) CD11b+CD11c-, (B) eosinophils, (C) CD11c+ST2L+ and 
(D) CD11c+TREM2+ was determined by flow cytometry *P<0.05. 
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Figure 4.18: Addition of CCL2 improves bacterial clearance from the airways and lung. 
PKH26-PCL (Sigma) dye that stains only phagocytic cells was i.n to BALB/c mice 72 hours 
before the first house dust mite (HDM) exposure and then mice exposed to three weeks of 
15µg HDM or 15µl PBS (3 times a week). 1µg of CCL2 was i.n 48 hours after final HDM 
exposure and 24 hours before infection. Mice were then infected with 1x10^6 CFU of 
Streptococcus pneumonia (D39) and analysed 48h after infection. (A) Experimental plan for 
CCL2 administration and bacterial infection. (B) Bacterial titres in the airways and lungs 
determined by plating on agar. Data representative of 4-5 mice per group and are 
representative of 3 independent experiments. (C) Percentage of mice with bacteria. Total (D) 
airway and (E) lung cells determined by trypan blue exclusion. *P<0.05. 
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Figure 4.19: Addition of CCL2 restores anti-bacterial immunity. PKH26-PCL (Sigma) 
dye that stains only phagocytic cells was i.n to BALB/c mice 72 hours before the first house 
dust mite (HDM) exposure and then mice exposed to three weeks of 15µg HDM or 15µl PBS 
(3 times a week). 1µg of CCL2 was i.n 48 hours after final HDM exposure and 24 hours 
before infection. Mice were then infected with 1x10^6 CFU of Streptococcus pneumonia 
(D39) and analysed 48h after infection. Percentage of live airway myeloid cells that are (A) 
neutrophils (CD11b+CD11c-Ly6G+SiglecF-) and (B) Eosinophils gated from FSC and SSC 
plots were determined by flow cytometry. Data representative of 4-6 mice per group and are 
representative of 2-3 independent experiments.  *P<0.05. 
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Figure 4.20: Anti-microbial substances after replenishment of macrophages in the 
allergic airways. (A-B) BALB/c mice were exposed to 15µg of HDM three times a week for 
three weeks. 48 hours after the final HDM exposure, allergen exposed mice were given 
intranasal FACS sorted CD11c+CD11b- airway macrophages either from naïve or allergen 
exposed lungs. 18 hours after the cell transfer mice were infected with 1x10^6 CFUs of 
Streptococcus pneumoniae (S.pn) strain D39. Surfactant protein-D (SP-D) and C – reactive 
protein (CRP) levels in the airways were measured by ELISA.  (C-D) PKH26-PCL (Sigma) 
dye that stains only phagocytic cells was i.n to BALB/c mice 72 hours before the first house 
dust mite (HDM) exposure and then mice exposed to three weeks of 15µg HDM or 15µl PBS 
(3 times a week). 1µg of CCL2 was i.n 48 hours after final HDM exposure and 24 hours 
before infection. Mice were then infected with 1x10^6 CFU of S. pneumonia (D39) and 
analysed 48h after infection. SP-D and CRP levels in the airways were measured by ELISA. 
Data presented as box and whisker diagrams. 
Chapter	  4:	  Probing	  macrophage	  dysfunction	  in	  the	  allergic	  lung.	  
	  
	  
135	  
4.3 Discussion 
The main finding of this chapter is that three weeks of HDM exposure changes 
resident alveolar macrophages into an alternatively activated phenotype that 
produces considerably less TNFα in response to TLR ligand stimulation. During the 
early stages of bacterial infection, the early cytokines TNFα and IL-1 are released. 
Many studies have shown TNFα to have a key role in S. pneumonia elimination. 
Anti-TNFα antibody administered against endogenous TNFα reduces survival by 
reducing neutrophil numbers and increasing bacteria240. TNF and IL-1 signalling 
receptor deficiency impairs S. pneumonia clearance and reduces neutrophil 
recruitment into the airspaces 239. TNF is also important in enhancing the release of 
other cytokines and chemokines from macrophages and other immune cells.  
In this chapter it was observed that alveolar macrophages present at the start of 
HDM exposure are also present 3 weeks later (dye+). Such alveolar macrophages 
defined as dye positive had increased mRNA and protein levels of RELMα, Ym1 and 
Arg1, which may signify alternative activation that may be driven by an environment 
rich in IL-4 and IL-13. Our data also strongly supports other studies showing 
enhanced IL-10 secretion275, expression of a number of anti-inflammatory receptors 
such as TREM2 187,	  ST2L and IL-27 receptor276 and inhibition of expression of pro-
inflammatory cytokines IL-1, TNFα, IL-6 and IL-12277. Other cytokines that enhance 
AAMs are IL-33, IL-25 and IL-21182 but were not studied directly here. Unfortunately 
such alternatively activated or regulatory macrophages are not conducive to anti-
bacterial immunity. For example, AAMs are linked to secondary bacterial 
pneumonia231 and have impaired phagocytosis278,279. Transfer of naïve airway 
macrophages restores anti-bacterial immunity in the HDM-allergic lung not only 
suggests a therapeutic strategy might be to recruit replacements or cause turnover 
of ones already there but also that macrophages are critical for immunity in the 
airway. 
Bone marrow derived immune cells, such as neutrophils and inflammatory 
monocytes appear early at the site of infection to promote innate immune responses 
and CCL2 is essential for the mobilisation of monocytes 280. CCL2 is also called 
monocyte chemoattractant protein-1 (MCP-1). Deletion of ccl2 reduces monocyte 
recruitment by 50% in Listeria infection 281. CCL2 deficient mice infected with 
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Escherichia coli have reduced bacterial clearance with reduced neutrophil and LTB4 
levels, whilst, addition of exogenous CCL2 in CCL2-/- improved bacterial elimination 
and neutrophil influx282. Furthermore, the addition of recombinant CCL2 to mice with 
allergic airways disease reduces total airway and lung cells and this correlated with a 
reduction in recruited CD11b+ airway cells compared to CD11c+ alveolar 
macrophages. Moreover, pre-treatment of mice with CCL2 reduces eosinophils. A 
study shows eotaxin-3 (eosinophil chemoattractant) binds to CCR2 (the CCL2 
receptor) and inhibits CCL2 mediated responses on human monocytes283. Although, 
mice do not have eotaxin 3, there is a possibility that CCL2 competes with 
endogenous mouse eotaxin to reduce eosinophil recruitment. The addition of CCL2 
also had an impact of CD11c+ alveolar macrophages by reducing their expression of 
ST2L and TREM2 while increasing expression of TLR2. Furthermore, addition of 
CCL2 did not allow bacteraemia to develop.  
CCL2 administration may have the potential to be used in therapy in man. CCR2 
(receptor for CCL2) deficiency shows enhanced allergic airway inflammation to 
Aspergillus fumigatus284 and OVA challenge/sensitisation285. As evidenced by data in 
this chapter administration of CCL2 after HDM but before bacterial infection is 
beneficial in combating S. pneumonia. Of course, further experiments are needed to 
elucidate and confirm the benefits of CCL2. For example, can a dose lower than 1µg 
per mouse of CCL2 exert the same effects? What are the consequences of giving 
CCL2 during HDM exposure rather than after the cessation of exposure? What are 
the effects of CCL2 on resolution after HDM exposure with/without bacterial infection 
and the side effects of treatment?  
TREM2 is expressed on AAMs and induced by IL-4 on peritoneal macrophages187. 
TREM2 deficient bone marrow derived dendritic cells produces more TLR-induced 
cytokines than WT dendritic cells 286. TREM2 on bone marrow derived macrophages 
inhibits through DAP12 261. Therefore, TREM2 expressed on alveolar macrophages 
could induce anti-inflammatory properties in alveolar macrophages. It is therefore 
pertinent that CCL2 reduces TREM-2 expression, which may be via CCR2 signalling 
on myeloid cells or be recruitment of fresh macrophages that become CD11c+ in the 
lung microenvironment but not TREM-2+ because of the reduced allergic 
environment. The same explanation could be used for the reduction of the IL-33 
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receptor ST2L (that impairs macrophage activation via TLRs by sequestering 
MyD88) in CCL2 treated mice. 
The restoration of TLR responses is unlikely to be due to a down-regulation of 
surface TLRs themselves, as there were no significant changes at mRNA level. We 
did however observe an upregulation of TLR negative regulators particularly A20. 
A20 targets TRAF-6 that is found upstream of NF-κB activation. Although the mRNA 
levels of TRAF-6 and IRAK-1 were not affected, the percentage of resident alveolar 
macrophages that express TRAF-6 and IRAK at the protein level are significantly 
less in the HDM exposed airways (<20%) than PBS controls (>40%). TRAF-6 and 
IRAK-1 could also be targeted by other inhibitors e.g. miR146 287. Therefore, alveolar 
macrophages were analysed for this miRNA and HDM exposure was found to induce 
miRNA146. It would be important to ascertain whether CCL2 administrations cause 
the recruitment of new macrophages where such TLR negative regulators are 
reduced. 
Overall, HDM exposure or the HDM induced immune response causes a number of 
changes (Fig. 4.21) in alveolar macrophages that could reduce their ability to 
respond to bacterial components that signal through TLRs. However, administration 
of macrophage chemoattractant protein significantly improves bacterial clearance 
possibly as a result of recruitment of new macrophages that are uninfluenced by the 
allergic response in the airways.  
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Figure 4.21: An illustration of the effects of HDM exposure on airway macrophages. Data in 
this chapter illustrates that after house dust mite exposure: alternatively activated 
macrophage markers YM1 and RELMα are highly expressed, there is increased messenger 
RNA levels of the TLR negative regulator A20 and reduced levels of TLR adaptor molecules 
TRAF6 and IRAK1. All these changes could play roles in reducing TNF cytokine production 
in response to TLR stimulation and may be driven by the up-regulation of microRNA species.  
 
 
Figure 4.22: CCL2 addition improves the proportion of alveolar macrophages in the airways 
that are uneducated by the allergic response. CCL2 administration reduces regulatory 
receptors on resident alveolar macrophages. These changes could enhance the anti-
bacterial capacity of alveolar macrophages.  
	  	  
	  
139	  
 
 
 
 
CHAPTER 5 
Reduced HDM-induced eosinophilic 
pathology does not restore anti-bacterial 
immunity. 
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CHAPTER 5 
5.1 Introduction  
T1/ST2 (the IL-33 receptor) is upregulated on airway macrophages from HDM-
exposed mice (chapter 4). IL-33, the ligand for ST2L288, is produced in a precursor 
form that is cleaved by caspase-193. IL-33-ST2L signalling leads to NF-κB and MAP 
kinases activation93. IL-33 increases eosinophil survival and ST2 blocking antibodies 
inhibit eosinophil responses to IL-33289. Furthermore, intranasal administration of IL-
33 induces airway hyper-reactivity and mucus production even in T cell deficient 
mice (RAG2-/-)290, therefore, IL-33 responsive innate immune cells have a critical 
role. Soluble human ST2 in sera correlates with asthma exacerbations291. IL-33 
signalling via ST2L plays an important role in allergic responses. For example, the 
levels of Th2 cytokines are decreased in allergic lungs by administration of ST2L 
blocking antibody101. ST2 deficiency causes mice to develop attenuated OVA-
induced airway inflammation. In response to OVA sensitisation and challenge, ST2 
knock outs have significantly less cellular infiltrate, macrophages and eosinophils 
than WT OVA exposed lungs292, this is in contrast to another study showing normal 
Th2 responses after OVA induced airway inflammation293. ST2-/- macrophages are 
not alternatively activated during airway inflammation induced by OVA sensitisation 
and challenge94. Therefore, IL-33-ST2 signalling is important in AAMs in response to 
OVA.  
IL-33 signals through ST2L and IL-1 receptor associated protein (IL-1RAcP) 
heterodimer and recruits MyD88 to ST2L, which activates downstream NF-κB and 
MAP kinase pathways288. sST2 is shown to act as a decoy receptor and inhibit LPS 
induced signalling294. IL-33 and ST2L signalling protects from parasitic infection. 
ST2-/- mice infected with Toxoplasma gondii has more severe pathology295. Lung 
innate lymphoid cells expressing ST2 are important in restoring epithelial integrity 
after influenza infection296. Furthermore, ST2L inhibition by monoclonal anti-ST2L 
treatment during RSV infection prevents Th2 pathology297. In contrast, ST2L-/- mice 
have a normal antibacterial response against respiratory infection with 
Mycobacterium tuberculosis298.     
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5.1.1 Hypothesis and Aims 
Since ST2 and its ligand, IL-33 are current targets in the treatment of allergic 
conditions we decided to elucidate this interaction further and its effect on anti-
bacterial immunity in the HDM-sensitised lung. It is not currently known whether the 
immune response to, or the allergen itself, is responsible for increased susceptibility 
to bacterial pneumonia and sepsis. The hypothesis for this chapter is that the allergic 
immune response plays a dominant role in susceptibility and that the initial effects of 
IL-33 is reduced in mice lacking functional ST2 given HDM, this restores anti-
bacterial immunity. The specific aims were: 
1. To assess the response to HDM in mice lacking functional ST2 and assess the 
allergic airway inflammation. 
2. To assess bacterial clearance in WT and ST2-/- mice following prior exposure to 
HDM.  
3. To study the cellular recruitment profile in the airways of ST2-/- with or without 
bacterial infection. 
4. To assess ST2-/- macrophages response to bacterial components.  
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5.2 Results 
5.2.1 Bacterial susceptibility in WT and ST2-/- mice  
ST2-/- mice (confirmed by genotyping Fig. 5.1) exposed to HDM had reduced 
cellular infiltrate and reduced total eosinophil numbers in the airways (Fig. 5.2). Both 
WT and ST2-/- mice exposed to PBS or HDM had bacteria in the airways 24 hours 
after S. pneumonia infection. However, 48 hours after infection only WT HDM and 
ST2-/-+HDM airways had bacteria (Fig. 5.3A & B). All groups had bacteria in the 
lungs except WT PBS 48 hours after infection. Therefore, ST2-/- PBS exposed mice 
(33%) had bacteria in the lungs while all the control (WT PBS) mice had eliminated 
the bacteria. Bacterial dissemination was present in both WT and ST2-/- HDM 
exposed groups 48 hours after infection (Fig. 5.3). However, 50% of the mice in WT 
HDM group developed bacteraemia whereas, only 28.5% of ST2-/- mice had 
bacterial dissemination (Fig. 5.3B). ST2-/- mice are thus still susceptible to bacterial 
complications but at a lower level than WT HDM exposed mice. Therefore, the 
cellular infiltrate to HDM in the presence or absence of ST2 was examined.  
There was reduced infiltration of leukocytes into the airways of ST2-/- mice 
compared to WT controls 48 hours after S. pneumonia infection (Fig. 5.4). WT+PBS 
had elevated numbers of cells in the airways after infection compared to numbers 
present at baseline (0h after infection), however, this increase in cell recruitment 
after infection was absent in WT+HDM exposed group (Fig. 5.4) as shown in the 
chapter 3. Similarly, ST2-/-+PBS had more cellular recruitment than ST2-/-+HDM 
compared to baseline (0 hour) levels (Fig. 5.4B). Thus ST2-/- HDM-exposed mice 
still display reduced cell recruitment.  
HDM exposure induces mucus production. At the time of infection, mucus staining 
was higher in the WT+HDM group compared to ST2-/-+HDM group (Fig. 5.5). 
However, 24 hours after bacterial infection both WT and ST2-/- HDM groups had 
similar levels of mucus production (Fig. 5.5).   
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Figure 5.1: ST2 knockout and wild-type control (BALB/c) genotyping. PCR image to 
confirm animals used in this chapter were ST2-/- homozygous knockouts. Representative 
three wild-type (WT) controls and four ST2-/- mice were ear punched and DNA extracted 
and PCR performed using REDExtract-N-Amp Tissue PCR kit (Sigma). The expected band 
for ST2 is at 300 bp in wild-type mice (lanes 1-3).  
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Figure 5.2: Reduced airway cellular 
infiltrate and eosinophils in ST2-/- 
compared to WT controls mice after 
HDM exposure. Wild-type BALB/c and 
ST2 deficient mice were exposed to 
15µg of HDM or 15µl PBS 3 times a 
week for 3 weeks. 72 hours after the 
final HDM exposure BAL was 
performed and analysed for (A) Total 
airway cells by trypan blue exclusion, 
(B) total eosinophil numbers by flow 
cytometry and (C) lung IL-33 levels by 
ELISA. Data shows the mean with 
SEM of n=10 mice per group. *P<0.05, 
** P<0.01, *** P<0.001. 
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Figure 5.3: Susceptibility of WT and ST2-/- to Streptococcus pneumonia after house 
dust mite exposure. Wild-type BALB/c and ST2 deficient mice were exposed to 15µg of 
HDM or 15µl PBS 3 times a week for 3 weeks. 72 hours after the final HDM exposure mice 
were infected with 1x10^6 CFU Streptococcus pneumonia and bacterial titres were analysed 
24 and 48 hours after infection by plating out airway lavage (BAL), lung and blood. n=5 at 
24h and n=8-9 at 48h. Data shows the mean with SEM.  
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Figure 5.4: Reduced infiltrated cell recruitment in ST2-/- after Streptococcus 
pneumonia infection compared to WT PBS group. Wild-type BALB/c and ST2-/- mice 
were exposed to 15µg of HDM or 15µl PBS 3 times a week for 3 weeks. 72 hours after the 
final HDM exposure mice were infected with 1x10^6 CFU Streptococcus pneumonia. Total 
airway cells by trypan blue exclusion are shown 24 hours after infection (A) numbers and (B) 
% of baseline (baseline = total cells at time of infection and 72hrs after final HDM exposure). 
Data presented as mean with SEM. *P<0.05, ** P<0.01, *** P<0.001. 
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Figure 5.5: Mucus production in the lungs of WT and ST2-/- before and 24 hours after 
infection. Wild-type BALB/c and ST2-/- mice were exposed to 15µg of HDM or 15µl PBS 3 
times a week for 3 weeks. 72 hours after the final HDM exposure mice were infected with 
1x10^6 CFU Streptococcus pneumonia. Histology shows Periodic Acid-Schiff (PAS) staining 
of lung tissue that was fixed in 10% formalin for 24 hours. Only HDM exposure induces 
mucus production in WT and ST2-/- groups. Magnification x40.   
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5.2.2 Increased neutrophil recruitment in the airways of ST2-/-+HDM compared 
to WT+HDM 
The percentage of neutrophils (CD11b+CD11c-Ly6G+SiglecF-) in the airways of 
ST2-/-+HDM group was higher than WT+HDM mice 24 hours after infection (Fig. 
5.6A). After infection, there were fewer neutrophils in HDM groups (WT and ST2-/-) 
compared to PBS controls 48 hours after S. pneumonia infection (Fig. 5.6C). The 
percentage of eosinophils (CD11b+CD11c-Ly6G-SiglecF+) was significantly reduced 
in ST2-/-+HDM group compared to both PBS (WT and ST2-/-) controls in the airways 
after infection eosinophils as percentage of total airway cells (Fig. 5.6B) and in total 
numbers compared to WT+HDM group (Fig. 5.6D). Thus despite a reduction in 
eosinophils and an increase in neutrophils, bacterial infection was still a problem in 
the HDM-exposed airway. 
Total lung cells were similar in all groups (Fig. 5.7A). The percentage of recruited 
CD11b+ lung cells that were Ly6G+SiglecF- (neutrophils) was significantly reduced 
in WT+HDM compared to WT+PBS; however, the difference in WT+PBS and ST2-/-
+HDM was not significant 24 hours after infection (Fig. 5.7B). The percentage of 
CD11b+ that were Ly6G-SiglecF+ (eosinophils) was significantly higher in HDM 
exposed groups compared to PBS controls (Fig. 5.7C). Lung neutrophil numbers 
were highest in WT+PBS group compared to the rest of the groups that had similar 
numbers (Fig. 5.7D). However, eosinophil numbers in ST2-/-+HDM were significantly 
reduced in comparison to WT+HDM (Fig. 5.7E). There was no difference in CD4+ 
and CD8+ T cell numbers in the lungs (Fig. 5.8). It is interesting to note that cell 
recruitment in ST2-/- mice to HDM or bacteria is blunted in general compared to WT 
mice suggesting a more generalised defect in these animals.  
 
 
Chapter	  5:	  Reduced	  HDM-­‐induced	  eosinophilic	  pathology	  does	  not	  restore	  anti-­‐bacterial	  immunity.	  
149	  
	  
 
 
Figure 5.6: Increased percentage of airway myeloid cells that are neutrophils in ST2-/- 
mice compared to WT controls. Wild-type BALB/c and ST2-/- mice were exposed to 15µg 
of HDM or 15µl PBS 3 times a week for 3 weeks. 72 hours after the final HDM exposure 
mice were infected with 1x10^6 CFU Streptococcus pneumonia. (A) CD11b+Ly6G+SiglecF- 
cells and (B) CD11b+Ly6G-SiglecF+ as percentage of airway myeloid cells and total airway 
(C) neutrophil and (D) eosinophil numbers 48 hours after infection were determined by flow 
cytometry. n=5 at 24 hours and n=12 at 48 hours per group. *P<0.05, ** P<0.01, *** 
P<0.001. 
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Figure 5.7: Neutrophils and eosinophils in the lungs of WT and ST2-/- mice 24 hours 
after Streptococcus pneumonia infection. Wild-type BALB/c and ST2-/- mice were 
exposed to 15µg of HDM or 15µl PBS 3 times a week for 3 weeks. 72 hours after the final 
HDM exposure mice were infected with 1x10^6 CFU Streptococcus pneumonia and 
harvested 24 after infection. (A) Total number of lung cells (by trypan blue exclusion), 
percentage of CD11b+ lung cells that are (B) Ly6G+SiglecF- or (C) SiglecF+Ly6G- and 
number of lung (D) neutrophils and (E) eosinophils was determined by flow cytometry. Data 
presented as box and whisker diagrams.  *P<0.05, ** P<0.01, *** P<0.001. 
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Figure 5.8: Lung T cells numbers after bacterial infection in WT and ST2-/- with or 
without HDM exposure. Wild-type BALB/c and ST2-/- mice were exposed to 15µg of HDM 
or 15µl PBS 3 times a week for 3 weeks. 72 hours after the final HDM exposure mice were 
infected with 1x10^6 CFU Streptococcus pneumonia and harvested 24 after infection. T 
lymphocytes in lung homogenate were identified as (A) CD3+CD4+CD8- or (B) 
CD3+CD8+CD4- T cells by flow cytometry. n=5 per group. *P<0.05.  
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5.2.3 Th2 cytokine levels in WT and ST2-/- lungs 
After bacterial infection the Th2 cytokine IL-13 was undetectable in the lungs (Fig. 
5.9). 0 hour after infection, the lungs of WT+HDM and ST2-/-+HDM group had 
detectable levels of IL-13 compared to PBS controls (Fig. 5.9B). Similarly, IL-33 
levels were significantly higher in lungs after HDM exposure before infection (Fig. 
5.9A). However, after infection the levels of IL-33 significantly increased in all groups 
and at this stage there was no difference in IL-33 levels between the groups (Fig. 
5.9A). WT+HDM, ST2-/-+PBS and ST2-/-+HDM had similar levels of TNFα in the 
airways 24 hours after infection and this level was significantly reduced compared to 
WT+PBS (Fig. 5.10). 
 
5.2.4 Reduced AAM markers in ST2-/- lungs and alveolar macrophages 
The data in the previous chapter showed an AAM skew of alveolar macrophages 
after HDM exposure. In ST2-/- alveolar macrophages, although the levels of Arg1, 
RELMα and YM1 RNA expression were significantly lower after HDM exposure 
compared to WT HDM, they did not reach baseline levels seen in PBS controls (Fig. 
5.11). This is also shown by whole lung mRNA analysis (Fig. 5.12). Thus, alveolar 
macrophages in the WT+HDM-exposed lung are altered strongly in phenotype 
towards alternatively activated or wound healing and much less so when the allergic 
immune response is attenuated e.g. in ST2-/-+HDM group.  
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Figure 5.9: Levels of IL-33 and IL-13 levels cytokines in the lungs.  Wild-type and ST2-/- 
BALB/c mice were exposed to 15µg of HDM or 15µl PBS 3 times a week for 3 weeks. 72 
hours after the final HDM challenge, mice were infected with 1x10^6 CFU Streptococcus 
pneumonia and harvested 24 hours after infection. Levels of cytokines; (A) IL-33 and (B) IL-
13 were analysed by ELISA.  *P<0.05, ** P<0.01, *** P<0.001. 
 
 
Chapter	  5:	  Reduced	  HDM-­‐induced	  eosinophilic	  pathology	  does	  not	  restore	  anti-­‐bacterial	  immunity.	  
154	  
	  
 
Figure 5.10: TNFα levels in the airways and lung of WT and ST2-/-.  Wild-type BALB/c 
and ST2-/- mice were exposed to 15µg of HDM or 15µl PBS 3 times a week for 3 weeks. 72 
hours after the final HDM challenge, mice were infected with 1x10^6 CFU Streptococcus 
pneumonia and TNF levels in the (A) airways and (B) lungs were analysed 24 hours after 
infection. n=5 per group.  *P<0.05, ** P<0.01, *** P<0.001. 
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Figure 5.11: Reduced mRNA expression of alternatively activated macrophage 
markers RELMα, Arg1 and YM1 in ST2-/- alveolar macrophages compared with WT 
after exposure to HDM.  BALB/c mice exposed to 15µg of HDM or 15µl PBS 3 times a 
week for 3 weeks. 72 hours after the final HDM challenge live CD11c+CD11b- alveolar 
macrophages were sorted by flow cytometry and stored in RNA lysis buffer+β-ME. TaqMan 
probes were used to detect the mRNAs. mRNA levels are expressed relative to 18S and a 
WT PBS control sample. Data presented as mean+/SEM representative of two independent 
experiments. n=4-5 per group of 2 independent experiments. *P<0.05, ** P<0.01, *** 
P<0.001.  
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Figure 5.12: Reduced mRNA expression of alternatively activated macrophage 
markers RELMα, Arg1 and YM1 in ST2-/- lungs compared with wild type after 
exposure to HDM.  BALB/c mice exposed to 15µg of HDM or 15µl PBS 3 times a week for 3 
weeks. 72 hours after the final HDM challenge whole lung was stored in RNA lysis buffer+β-
ME. TaqMan probes were used to detect the mRNAs. mRNA levels are expressed relative to 
18S and a WT PBS control sample. Data presented as mean+/-SEM representative of two 
independent experiments. n=4-5 per group of 2 independent experiments.  *P<0.05.  
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5.2.5 ST2-/- alveolar macrophage features  
CD11c+ alveolar macrophages expressed significantly lower levels of TLR2 and 
higher levels of TREM2 after HDM exposure in both WT and ST2-/- groups (Fig. 
5.13A & C). However, the percentage of airways myeloid cells that were 
CD11c+TLR2+ were reduced in WT+HDM compared to ST2-/-+HDM (Fig. 5.13B). In 
contrast, the percentage of airway myeloid cells that were CD11c+TREM2+ was 
significantly higher in ST2-/-+HDM compared to WT+HDM (Fig. 5.13D).  
In the last chapter, it was found that alveolar macrophages from the HDM exposed 
airways produced less TNFα in response to TLR stimulation compared to PBS 
exposed alveolar macrophages. Here, the response of CD11c+CD11b- (alveolar 
macrophages) airway cells was assessed from WT and ST2-/- to overnight TLR 
stimulation. Overall, WT+HDM exposed alveolar macrophages produced less TNFα 
compared to WT+PBS (Fig. 5.14) as shown in chapter 4. WT+PBS cells produced 
less TNFα compared to ST2-/-+PBS group after TLR stimulation (Fig. 5.14). Alveolar 
macrophages from ST2-/-+HDM produced lower levels of TNFα compared to ST2-/-
+PBS in response to TLR4 and TLR1/2 stimulation (Fig. 5.14). 
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Figure 5.13: TLR2 and TREM2 expression on CD11c+ airway cells. Wild-type BALB/c 
and ST2-/- mice were exposed to HDM three times a week for 3 weeks. TLR2 and triggering 
receptor expressed on myeloid cells (TREM2) were analysed 72 hours after final HDM 
exposure. Data is shown (A) TLR2 and (C) TREM2 expression as percentage of airway 
CD11c+ cells and (B) CD11c+TLR2+ and (D) CD11c+TREM2+ as percentage of airway 
myeloid cells. n=5 per group of 2 independent experiments. *P<0.05, ** P<0.01 
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Figure 5.14: TNFα release by CD11c+CD11b- airway cells in response to LPS and LTA 
stimulation. Wild type and ST2-/- BALB/c mice were exposed to PBS or HDM 3 times a 
week for 3 weeks. 72 hours after the final HDM exposure, CD11c+CD11b- airway cells were 
sorted by flow cytometry. 3x104 cells per well were plated out and stimulated with 1µg/ml 
TLR4 ligand LPS and 1µg/ml TLR2 ligand LTA. TNFα release by the cells was measured by 
ELISA. Data presented as mean with SD. Representative of 2 experiments. *P<0.05, ** 
P<0.01, *** P<0.001. 
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5.3 Discussion  
The effect of HDM exposure in ST2 deficient mice was less marked than WT 
controls. A significant reduction in HDM induced cellular recruitment and in particular 
eosinophils was present in ST2 deficient mice. Therefore, it might be expected that 
lacking a receptor that binds IL-33 that in turn drives allergic disease would be of 
benefit in subsequent bacterial infection. In HDM-exposure of the lung followed by 
Streptococcus pneumonia infection, this appears not to be the case. In this chapter, 
fewer ST2-/- mice exposed to HDM have bacteraemia 48 hours after bacterial 
infection, whereas, 50% of WT HDM controls had bacteria in the blood. Both WT and 
ST2-/- HDM exposed groups had bacteria in the airways and lung 48 hours after 
infection.  
ST2 deficiency does protect from secondary lung infection during sepsis in a murine 
model of cecal ligation and puncture induced sepsis followed by a secondary 
respiratory infection with Pseudomonas aeruginosa 299. This study showed that cecal 
ligation and puncture reduces IFN-γ and TNFα production from T cells, whereas this 
was absent in ST2 deficient mice 299. In contrast, another study shows ST2 
deficiency increases susceptibility to polymicrobial sepsis as a result of impaired 
phagosome maturation and reactive oxygen species production in ST2-/- phagoctyes 
300. This may explain the heightened bacterial numbers in ST2-/- PBS exposed mice 
in the lungs 48 hours after S. pneumonia infection compared to WT PBS controls. 
Furthermore, ST2 deficient mice infected with influenza A virus have a comparable 
recovery pattern to WT controls but display higher bacterial titres after subsequent 
pneumococcal pneumonia associated with increased lung IFN-γ levels301. A recent 
study show increased cytokine secretion by the ST2 deficient cells using whole blood 
leukocytes from WT and ST2-/- mice stimulated ex vivo with S. pneumonia302. Taken 
together these studies highlight the importance of the possible protective effect of IL-
33/ST2 signalling after bacterial infection. Although, ST2L signalling does not seem 
to be critical after lung Mycobacterium tuberculosis infection, ST2 deficient mice 
display a normal host immune response298. These data exemplify the complexity of 
innate immunity receptors.  
LPS-induced shock in vivo is dramatically reduced after administration of soluble 
ST2 that would presumably mop up IL-33; whereas, administration of anti-ST2 
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antibody (that binds, but it is unclear if it inhibits or signals through ST2) exacerbates 
LPS-induced inflammation 303.  Increased soluble ST2 in serum is seen in patients 
with sepsis 304. Administration of ST2 ligand, IL-33 reduces sepsis by increasing 
neutrophil influx for better bacterial clearance, this occurs as a result of IL-33 
preventing downregulation of CXCR2 305. In our model, the levels of IL-33 may not 
have a major role, as after bacterial infection all groups had similar levels of IL-33 in 
lung homogenate.  
ST2L expression is induced on macrophages by IL-13 and promotes differentiation 
into AAMs94. In vivo, HDM exposed ST2-/- alveolar macrophages expressed less 
RELMα, YM1 and Arg1 mRNA levels compared to WT HDM controls. This may 
explain the improved response of ST2-/-+HDM exposed alveolar macrophages to 
TLR2 and 4 agonists, compared to WT+HDM. This is supported by observations that 
peritoneal macrophages from ST2-/- mice cultured with IL-1α, IL-1β or LPS produce 
more pro-inflammatory cytokines (IL-6, IL-12 and TNFα) than WT controls 306. ST2-/- 
macrophages could produce more TNFα than WT controls due to less sequestering 
of MyD88 and MAL 306, adaptor molecules involved in the TLR signalling pathway. 
MyD88 is required for NF-κB activation by TLR2, TLR4 and TLR9. By affecting 
MyD88 and MAL, ST2L will prevent signalling through IRAKs, TRAF6 and NF-κB 
and inflammatory gene expression. By contrast addition of IL-33 to peritoneal 
macrophages enhances LPS and LTA induced TNFα release 307. Whether ST2 
promotes or inhibits TLR responses is currently confusing and seems to depend on 
whether it is the receptor or ligand that is blocked.  
In summary, ST2 signalling is important in eosinophil recruitment in response to 
allergen exposure since deficiency in this receptor impairs eosinophil recruitment into 
the airways. However, despite a reduction in HDM induced allergic inflammation the 
impact of ST2 deficiency on protection against bacterial pneumonia is limited. 
Therefore, this pathway does not appear to be critical hindrance to anti-bacterial 
immunity in the lungs of HDM exposed mice. Nonetheless the effect of ST2 seems to 
be important in protection against S. pneumonia infection shown by increased 
bacterial susceptibility of lungs without functional ST2.  
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CHAPTER 6 
6.1 Final Discussion  
Bacteria are associated with asthma exacerbations, but the mechanisms responsible 
are unknown. Our data shows delayed clearance and increased invasiveness of S. 
pneumonia in the murine lung undergoing inflammation induced by chronic exposure 
to HDM. This “asthma exacerbation of bacterial infection” rather turns the concept of 
microbial exacerbation of asthma on its head. There is also clinical support for this 
scenario in that individuals with asthma have a greater than 2-fold increased risk of 
invasive pneumococcal disease16. This study identified S. pneumoniae as the most 
prevalent bacterium. There is currently a discrepancy with other models of allergic 
airway inflammation. The murine OVA model of sensitisation shows reduced 
susceptibility to S. pneumonia 220,222. In addition, S. pneumonia before OVA 
challenge induces T regulatory cells in lymph nodes and suppresses allergic airway 
disease308. However, OVA is not a clinically relevant allergen, requires 
intraperitoneal priming and does not contain the complex mix of allergen, enzymatic 
activity and TLR agonists common in most clinically relevant allergens like HDM. 
Therefore, HDM allows us to study a clinically relevant allergen that affects lung 
mucosal immune cells.   
The main findings of this thesis are that HDM exposed lungs have increased 
susceptibility to S. pneumonia and that the molecular pathways leading to the 
production of neutrophil chemoattractants in the lung are compromised. Despite the 
complexity of anti-bacterial pathways that are disrupted, the re-introduction of 
neutrophils by i.n administration of neutrophil chemoattractants to airways with 
allergic airway disease enables clearance of S. pneumoniae that would otherwise 
prove fatal.  
 
6.2 Specific innate immune pathways are modulated in the allergic lung that 
precipitates life threatening bacterial pneumonia and sepsis 
HDM exposure modifies anti-bacterial pathways in the allergic airway disease that 
impact on subsequent control of respiratory bacteria. The HDM exposed lung 
recruits considerably fewer neutrophils than PBS controls. Blockade or depletion of 
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neutrophils is fatal in bacterial pneumonia 142. The inability to recruit neutrophils 
could be a result of reduced neutrophil recruiting cytokines and chemokines such as 
TNF and CXCL2 present in the HDM exposed airways after bacterial infection. The 
lack of involvement of IL-17A in our study was surprising since this cytokine is 
involved in neutrophil recruitment in another lung allergic/infection models309. This 
latter study, however examines Haemophilus influenzae administered during OVA 
peritoneal sensitisation, but before allergen challenge and does not examine the 
effect of established allergy on bacterial clearance.  
 
Alveolar macrophage alterations in the allergic lungs may also contribute to the 
reduced neutrophil recruitment following bacterial infection as they secrete neutrophil 
recruiting cytokines. Alveolar macrophages are long lived cells with a slow turnover 
177. The reduced responsiveness to TLR ligands after HDM exposure will therefore 
impact on antibacterial immunity for significant periods of time. Furthermore, even 
with turnover, their replacements may be conditioned by the allergic lung to be 
equally affected.   
 
HDM exposure results in prolonged phenotypic and functional changes in murine 
alveolar macrophages that reduce their ability to respond to PAMPs. Alveolar 
macrophages (CD11c+ airway cells) have reduced levels of TLR2 after three weeks 
of HDM exposure compared with PBS controls. Surprisingly, neutrophils also have 
reduced TLR2 levels during bacterial challenge of HDM-exposed mice compared to 
non-allergic controls. This may suggest that it is the altered environment that affects 
immune cells and not on inherent deficit in the cells themselves. Future studies 
should address whether the altered TLR responsiveness is restricted to TLR2 or 
extends to others that use different signaling pathways.  
 
In addition alveolar macrophages from the allergic lung express higher levels of 
regulatory receptors CD200R, ST2L and TREM2 that limit myeloid cell activity and 
reduce anti-bacterial cytokine secretion. Blockade of these receptors in the allergic 
lung and analysis of bacterial susceptibility should be tested in the future as it may 
be possible to re-educate alveolar macrophage responsiveness. Moreover, alveolar 
macrophages gain an alternatively activated phenotype in the allergic lung 
determined by increased mRNA and protein levels of RELMα, Arg1 and YM1. 
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Functionally these macrophages are not able to produce as much TNFα in response 
to TLR agonists as PBS exposed alveolar macrophages. An increase in these TLR 
regulatory proteins will impact the level of activation of NF-κB (and other transcription 
factors) and therefore, anti-bacterial cytokine and chemokine responses. In vitro, 
direct exposure of naïve alveolar macrophages to HDM overnight did not reduce 
their capacity to produce TNFα after TLR 2 and 4 stimulation. This again points to 
effects of an altered or more complex microenvironment of the lungs after HDM 
exposure than direct impact of HDM on alveolar macrophages.  
 
There is a possibility that the reduced responsiveness to TLR ligands is a result of 
TLR cross-tolerance, which is a process whereby TLR-activated cells are, for a short 
period of time, refractory to subsequent TLR stimulation310. Der p2 and Der p7 have 
structural and functional homology with MD-2; the LPS binding component of the 
TLR4 signaling complex 311,312 and HDM extracts contain low levels of LPS and so it 
is possible that there is a similar refractory effect via TLRs alone. However, chronic 
pulmonary LPS (1µg) exposure for 4 consecutive days and then challenge with 10µg 
of LPS 24 hours later results in only a selective immunosuppression without affecting 
the neutrophilic response313. Additionally, LPS tolerance does not cause tolerance to 
TLR2 ligands such as Pam3Cys 313. 
 
If macrophage responsiveness is the problem, then we should be able to rectify the 
situation by replacing them. Transfer of naïve alveolar macrophages prior to bacterial 
challenge in HDM-exposed mice reduced bacterial titres compared to mice receiving 
HDM-exposed alveolar macrophages. However, the increase in alveolar 
macrophages seemed to be beneficial whether naïve or allergic. From this we can 
conclude that fresh macrophages, or more allergic ones (albeit producing less 
chemokines) is beneficial in combating bacterial growth and spread. Another way of 
increasing airway macrophages is to increase monocyte release from the bone 
marrow by CCL2 280. Indeed, CCL2 administration before bacterial infection 
prevented bacteraemia 48 hours after infection. The defect in the allergic lung can 
therefore be overcome by manipulating macrophage numbers in the airspaces. This 
does not mean they are the only defect, but they are sufficient to overcome the 
problems that exist.  
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Future studies should address whether airway macrophage turn over or recruitment 
can be improved in models of allergy. Despite our studies showing that anti-bacterial 
immunity improves the longer the gap between the last allergen exposure, in reality, 
in patients the problem is likely to persist as allergen may be ubiquitous.  
  
6.3 Bacterial pneumonia in a murine model of reduced house dust mite 
induced airway inflammation  
In chapter 5, we addressed whether it is the Th2 environment that causes bacterial 
complications or the HDM itself. Previous studies show that administration of 
monoclonal ST2 antibody reduces the severity of RSV in allergic mice297. 
Furthermore, IL-33 treatment in mice infected with influenza virus resulted in 
considerably reduced lung inflammation (Hussell et al, unpublished observations). In 
addition, administration of neutralising antibody against ST2 in an OVA model of 
airway inflammation attenuates eosinophilic inflammation and mucus 
hypersecretion92 and reduces Th2 cytokine production 98. However, when the OVA 
model of allergic inflammation was used in ST2 knockout mice, allergic inflammation 
was unaffected293. In contrast, another OVA study in ST2-/- mice shows attenuated 
inflammation292. The differences between these two studies could be a result of 
different OVA sensitisation and challenge protocols. In this thesis we how that HDM 
induced eosinophilic inflammation is lower in ST2-/- mice compared to wild type 
controls. Though both wild type and ST2-/- mice exposed to HDM developed 
bacterial pneumonia in the lungs 48 hours after infection, fewer ST2-/- HDM mice 
had bacteria in the blood compared to PBS controls. An absence of the IL-33R, 
ST2L, therefore reduces but does not fully eliminate bacterial complications after 
HDM exposure.  
 
ST2 knockout mice had reduced TLR2 expression on alveolar macrophage, but not 
as profound as in WT mice. Similarly, mRNA levels of AAM markers Arg1, YM1 and 
RELMα are significantly lower in ST2-/-+HDM compared to WT+HDM alveolar 
macrophages. In response to TLR2 and TLR4 agonists, alveolar macrophages from 
ST2-/- group produced more TNF than WT controls. This suggests that alveolar 
macrophages are less affected in the reduced allergic airway inflammation in ST2-/- 
mice, which improves handling of bacteria. However, a lack of ST2 does not 
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completely remove the problem. Future studies should address macrophage 
production of neutrophil chemoattractants in this model.  
 
6.4 Asthma therapeutics and bacterial exacerbation 
Asthma is a complex disease encompassing a number of different subtypes. Despite 
better understanding of asthma pathogenesis, the main therapy remains inhaled 
corticosteroids, beta-2 agonists and long-acting bronchodilators. These reduce 
symptoms and the frequency of exacerbations, but many patients remain highly 
symptomatic and these therapies have little impact on the decline in lung function. 
Many studies in mice show a reduction in allergic inflammation by manipulating 
cytokines such as IL-4, IL-5 and IL-13, but the underlying dysfunction in airway 
hyper-responsiveness, neurons and smooth muscle cells is either not studied or 
unaltered. Neutralising these cytokines that dominate in overt disease have proved 
successful in specific groups of patients 314. For example, in patients with severe, 
steroid-resistant, eosinophilic asthma, anti-IL-5 (Mepolizumab) significantly reduced 
asthma exacerbations; this was in contrast to the same treatment in milder 
asthmatics315. Similarly, anti-IgE monoclonal antibody (omalizumab) is only effective 
in a small patient population of difficult-to-treat asthma314. Such findings reinforce the 
importance of employing patient specific treatments. One deficit in the literature 
regarding cytokine blockade in patients is whether subsequent bacterial 
complications are reduced, which requires longitudinal follow up studies. In other 
words, the underlying asthma may not have changed in clinical trials of severity but 
downstream complications, such as bacterial exacerbation may have improved.  
 
6.5 Conclusion of HDM- induced innate mechanisms increasing bacterial 
susceptibility in the allergic lung and areas suitable for therapeutic 
manipulation.  
If Streptococcus pneumonia gains entry into the lungs undergoing an allergic 
immune response, there are a number of factors that could increase the threshold of 
initiation of an effective antibacterial response (Fig. 6.1). Many allergens have 
protease activity and can cleave the epithelial tight junctions molecules102 such as 
claudin increasing penetration of the allergen and subsequently other pathogens into 
the lungs (Fig. 6.1A). HDM is often associated with TLR agonists such LPS89. TLR 
(or other, PRRs) signalling on epithelial cells and macrophages induces NF-κB 
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activation and subsequent cytokine release. Epithelial derived cytokines IL-25, IL-33 
and TSLP stimulate innate lymphoid cells (ILC)316 and alternatively activate 
macrophages leading to secretion of IL-13 (Fig. 6.1B). All of these reduce the 
antibacterial capacity of alveolar macrophages. Our data shows alveolar 
macrophages from HDM exposed lungs have lower TLR2 expression, therefore their 
detection of bacterial component LTA maybe impaired and also they express more 
alternatively activated proteins Arg1 and YM1 (Fig. 6.1C). Dendritic cells sample the 
airway lumen by forming dendritic extensions between epithelial cells. TSLP also 
conditions dendritic cells to release CCL17 and CCL22 to recruit T helper 2 (Th2) 
cells317. Th2 cells have limited antibacterial effects compared to Th1 cells (Fig. 
6.1D). Th2-associated cytokines IL-4, IL-5, IL-9 and IL-13 have an important role in 
the pathogenesis of allergic airways disease. These cytokines are involved in 
prolonging the survival of eosinophils, activation of mast cells and induction of goblet 
cell hyperplasia. Eosinophils and mast are critical in helminth infections but they 
have limited role in anti-bacterial immunity318 (Fig. 6.1E). In resolution of allergic 
airway response, resident macrophages uptake and clear apoptotic cells from the 
lung while releasing TGF-β, IL-10 and prostaglandin E2 involved in lung structural 
changes319. However, these mediators are anti-inflammatory and can dampen 
antibacterial mechanisms. Disrupted epithelial tight junctions allow basolateral 
epithelial growth factor to reach its receptor (EGFR) on the apical side. EGFR 
signalling in epithelial cells releases TGF-β, which activates fibroblasts to 
differentiate into myofibroblasts (sensitises more extracellular matrix components)320. 
Damaged epithelial cells (and innate lymphoid cells) also secrete amphiregulin that 
can bind EGFR and promote airway remodelling 296 (Fig. 6.1F & G). Remodelled 
airways cause structural changes that will impact on the immune response against 
respiratory bacteria.   
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Figure 6.1: Possible factors involved in bacterial exacerbation in the allergic lung. If 
Streptococcus pneumonia gains entry into the lungs undergoing an allergic immune 
response, there are a number of factors that could increase the threshold of initiation of an 
effective antibacterial response- highlighted below. A. Many allergens can cleave the 
epithelial tight junctions molecules and subsequently other pathogens into the lungs. B. TLR 
signalling on epithelial cells induces NF-κB activation and subsequent cytokine release. IL-
25, IL-33 and Thymic stromal lymphopoietin (TSLP) stimulate innate lymphoid cells and C. 
alternatively activate macrophages leading to secretion of IL-13, reducing the antibacterial 
capacity of alveolar macrophages. D. TSLP also conditions dendritic cells to release CCL17 
and CCL22 to recruit T helper 2 (Th2) cells. Th2 cells have limited antibacterial effects 
compared to Th1 cells. E. Th2-associated cytokines IL-4, IL-5, IL-9 and IL-13 are involved in 
prolonging the survival of eosinophils, activation of mast cells and induction of goblet cell 
hyperplasia. Eosinophils and mast are critical in helminth infections, they have limited role in 
bacterial infections. F. In resolution, resident macrophages uptake and clear apoptotic cells 
from the lung while releasing transforming growth factor (TGF)-β, IL-10 and prostaglandin E2 
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(PGE2) involved in lung structural changes. G. Damaged epithelial cells (and innate 
lymphoid cells) also secrete amphiregulin that can bind EGFR and promote airway 
remodelling. Remodelled airways involve structural changes that will impact on the immune 
response against respiratory bacteria.   
 
6.6 Future work 
The next set of experiments that can carry forward the theme of this thesis is 
assessing S. pneumonia susceptibility in mice deficient in key allergic airways 
disease associated cytokines such as IL-33 and IL-13. Furthermore, HDM has a 
substantial effect on alveolar macrophages and their role can further be assessed by 
macrophage depletion studies.  
We were unable to assess lung function in this thesis because we did not have the 
equipment in category II facility. However, it will be useful to measure lung function 
as a functional correlate to cellular and structural changes in the airways. 
The role of airway epithelial cells in initiating an effective bacterial response should 
be characterised including the response of airway epithelial cells to S. pneumonia 
and TLR ligands in vitro and in vivo by assessing cytokine/chemokine (TNF and 
CXCL2) and anti-microbial peptide (CRAMP and β-defensins) release and also the 
impact of HDM proteases and S. pneumonia virulence factors on epithelial tight 
junctions. 
In chapter 5, ST2 deficient mice were used to assess the impact of attenuated 
allergic airway inflammation on susceptibility to bacterial infection. We could take this 
work further and assess the impact of an allergen with (HDM) and without (OVA) 
protease activity on bacterial susceptibility.  
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